

CUMULATIVE INDEX 1998

Volume 21

March	SCHIZOPHRENIA, pages 1-257
June	PSYCHONEUROENDOCRINOLOGY, pages 259-515
September	DIAGNOSTIC DISORDERS, PART I, pages 517-723
December	DIAGNOSTIC DISORDERS, PART II, pages 725-1002

Note: Page numbers of article titles are in **boldface** type

- Abnormal illness behavior, deception in, 874-875
 - motives for, 874
- Acetylcholine (ACh), and growth hormone release, 329-330
- Acromegaly, psychiatric presentation in, 913
 - psychologic complications of, 482
- ACTH. See *Adrenocorticotrophic hormone (ACTH)*.
- Activities of daily living/instrumental activities of daily living (ADL/IADL), evaluation of, in older adult, 943-944
- Addison's disease, psychiatric presentation in, 910
- Adolescence, comorbidity and co-occurrence in, abnormal-normal boundaries and, 917
 - inattention, impulsivity, and hyperactivity in, attention deficit-hyperactivity disorder misdiagnosis in, 919-920
- issues overlooked in, 917
- missed diagnoses in, **917-926**
 - attention-impulsivity and hyperactivity and, 919-920
 - bipolar disorder, 922-923
 - developmental issues and, 919
 - hallucinations and, 920-922
 - informants and, 918
 - Internet and, 918-919
 - substance abuse, 923-924
- psychoneuroendocrinology in, **435-441**
- schizophrenia in, diagnostic issues in, 45-46
 - from neurodevelopmental abnormalities, 103-104
 - prevalence of, 44
 - versus bipolar disorder, 45
- Adolescent Dissociative Experiences Scale, 921
- Adrenal gland, in depression, brain imaging of, 466-467
 - enlargement of, 466-467, 496
 - hypertrophy of, 466
- Adrenal insufficiency. See *Hypocortisolism (adrenal insufficiency)*.
- Adrenal system disorders, psychiatric presentation of, 909-910
- Adrenal system disorder(s),
 - adrenocorticotrophic hormone in, 479
 - corticotropin-releasing hormone in, 479
 - hypercortisolism, 479-480 See also *Cushing's syndrome*
 - hypocortisolism, 480
- Adrenocortical insufficiency (hypocortisolism). See *Hypocortisolism (adrenal insufficiency)*.
- Adrenocorticotrophic hormone (ACTH),
 - activity and function of, 466
 - chronic stimulation of, adrenal hypertrophy with, 466
 - in schizophrenic patients, pharmacologic probe of, 20
 - secretion of, 418-419
 - stress effect on, 419
 - regulatory role of, in eating, 526
 - response to cortisol-releasing hormone, in trauma, 362-363
 - secretion from corticotrophs, 262
- Adrenocorticotrophic hormone (ACTH) receptor, in synthesis and secretion of glucocorticoids, 261-262

- Advanced sleep-phase syndrome,
definition of, 602
- Advocacy, recovery, consumerism
challenges, for schizophrenia,
advanced directives and, 244-245
communality of interests in, 243-245
consumer versus survivor and, 242
consumer-family frictions in, 241-243
emerging voices in, 235-236
Equal Employment Opportunity
Commission and, 243-244
expatient movement split, 239-236
family movement in, 240-241
historical roots of, 236-238
informed consent and, 242
mainstreaming of patients, 236-237
mandated treatment and, 242
organizations of discharged patients,
237
personal experience of, 234-235
President's Commission on Mental
Health, 238-239
recovery approach in, 245-246
Affective deficits, in schizophrenia, 38-39
Affective disorders, seizures and, 631
versus schizophrenia, brain imaging
studies of, 87
Afferent(s), in regulation of hypothalamic-
pituitary-adrenal axis, brainstem
and medullary, 263-264
circumventricular, 264-265
forebrain, 264-265
hypothalamic, 264
African Americans, substance use and
abuse among, 810-812
Aggression, in adults and children, cortisol
in, 436
in children and adolescents, serotonin
dysregulation in, 438
in parasomnias, 600-601
serotonergic function with, 438
Agitation, in schizophrenia, treatment
guidelines for, 210-211
AIDS dementia, violence in, 570
Alcohol abuse, manifestations of, 813-815
obsessive compulsive illness and, 796-
797
Alcohol use, increase with premenstrual
symptoms, 584-585
violence with, 568
Alzheimer's dementia, evaluation of,
951-952
hypercortisolemia and hippocampal atro-
phy in, 468-469
prevalence of, 949
recognition of, DSM-IV criteria for, 949-
950
treatment of, 952-953
nonpharmacologic, 953
pharmacologic, 952-953
Amenorrhea, hypercortisolemia in, 312
in eating disorders, 383
stress-induced, similarity with depres-
sion, 312-315
American Psychiatric Association
Guidelines, comparison with Expert
Consensus Guidelines, for content,
217-218
for language, 216
for methodology, 216
for schizophrenia treatment, 206
Amnesia, dissociative, 849-850
dissociative disorders and, 637-639
postconcussion, 611
traumatic, 849
Amnesic disorders, cognitive executive
circuitry in, 559
Amphetamines, abuse of, manifestations
of, 813-815
for attention deficit hyperactivity disor-
der, 770
violence and, 568
Amygdala, central nucleus and projections
of, cortisol-releasing factor regulation
of, 401-402
Anabolic steroids, abuse of, 813-815
long-term effects of, 829-830
violence and, 569
Anabolic-androgenic steroid abuse, and
psychopathology, 829-833
mood disorders with, case example,
830-831
narcissistic traits in, 832
personality psychopathology and, 831-
832
psychological motivations for, 830-831
ANF. See *Atrial natriuretic factor (ANF)*.
Anger, in psychiatric disorders, 545
Anorexia nervosa, amenorrhea in, 912-913
clinical description of, 381-382
CNS neuropeptide function in, 383-384
corticotropin releasing hormone in, 387
criteria for, 381
dynorphin in, 387-388
 β -endorphin in, 387-388
gonadal-releasing hormone in, 314
leptin in, plasma and cerebrospinal fluid
concentrations of, 385-386
MR imaging in, 469-470
neuroendocrine studies in, 382-383
neuropeptides in, 384-385
relationship to symptoms, 389-391
opioid peptides in, 387-388
oxytocin in, cerebrospinal levels of, 389
psychoneuroendocrinology of, CNS role
in, 381-396
underweight, vasopressin levels in, 388-
389

- ventricular enlargement and relationship to hypothalamic-pituitary-adrenal axis in, 469-470
- Anosognosia, 38-39
- brain areas in, 39
- Anticonvulsants, pseudoseizure response to, 651
- Antidepressants, in factitious disorder, 881-882
 - potentiation and augmentation of, thyroid hormones in, 283-284
 - selection of, for older adults, 965
- Antipsychotic drugs (APDs), atypical, adjunctive use of, 170-171
 - clozapine, 156-157
 - desired actions for, 157-161
 - early ideas about, 153-154
 - first, 154-157
 - in cognitive impairment, 160-161
 - in neuroleptic treatment-resistant patients, 157-158
 - mechanisms of atypicality and, 161-162
 - sulpiride, 155-156
 - thioridazine, 155-156
- cost of, traditional versus new, 182
- need for advances in, 151-153
 - extrapyramidal side effects and, 152
 - tardive dyskinesia and, 153
- new, pharmacology of, 155
 - therapeutic efficiency and, 183
- novel, for schizophrenia, 151-180
- novel atypical, 161-171
 - functionally selective dopamine agonists, 168
 - GABA agonists, 169
 - glutamatergic agonists, 169
 - MDL 100,907, 167
 - mixed compounds, 162-165
 - olanzapine, 162-163
 - presynaptic and partial dopamine agonists, 167-168
 - quetiapine, 164-165
 - risperidone, 165-166
 - sertindole, 166-167
 - with serotonin receptor antagonist properties, 165-167
- pharmacoeconomic evaluation of new, 183-194
 - activities in drug decision-making and, 183-184, 186
 - areas of clarification for, 185
 - pharmaceutical industry financing of, 186
 - recommendations for, 198-199
 - short-term efficacy versus long-term effectiveness of, 183-184
 - study goals for, 185-186
- Antisocial personality disorder, descriptions of, 775, 781
- exclusionary conditions for, 784
- lying in, 873
- necessary conditions for, 783
- Antithyroid antibodies, and mood disorders, 282
- Anxiety, anticipatory, cortisol-releasing factor overactivity in, 402-403
 - from abuse in childhood, 935
 - in adolescence, missed diagnosis of, 920
 - in diabetes mellitus, 912
 - in hyperprolactinemia, 482-483
 - in hyperthyroidism, 908
 - in pheochromocytoma, 910
 - in premenstrual syndrome, 581-582
 - in psychiatric disorders, 545
 - severe, mimic of pseudoseizure, 652-653
- Anxiety disorder(s), 737-741. See also *Panic disorder; Posttraumatic stress disorder (PTSD)*.
 - atrial natriuretic factor in, 404-405
 - childhood manifestations of, 936-937
 - cholecystokinin in, 404
 - cognitive executive circuitry in, 560
 - developmental origins of, non-human primate model for, 405-406
 - functional-anatomic correlates of, 399-400
 - growth hormone deficiency and, 482
 - growth hormone release in, 398
 - hypothalamic-pituitary-adrenal axis, and extrahypothalamic cortisol-releasing hormone in, 401-402
 - hypothalamic-pituitary-somatotropin axis in, 397-399
 - in diabetes mellitus, 481
 - neuroactive steroids in, 403-404
 - noradrenergic function in, 399
 - obsessive-compulsive disorder, neuroimaging in, 737-739
 - pentagastrin in, 404
 - posttraumatic stress disorder, neuroimaging in, 739-741
 - psychoneuroendocrinology of, 397-412
 - seizures and, 631-632
- APDs. See *Antipsychotic drugs (APDs)*.
- Apomorphine, as probe, of
 - adrenocorticotrophic hormone and cortisol, 420
 - of growth hormone activity, 414-415
 - of prolactin secretion, 417
- Apomorphine challenge, for vasopressin secretion, in schizophrenia, 410-421
- Arginine vasopressin (AVP), activation in panic, 403
- Asian Americans/Pacific Islanders, substance use and abuse among, 810-812
- Asperger's syndrome, childhood misdiagnosis of, 928-931

- Asperger's syndrome (*Continued*)
 definition of, 928
 in adults, description of, 928-929
 Association cortex, in schizophrenia,
 pathomorphology of, progressive, 100,
 102-103
 Asthma, PMS effect on, 585-596
 Atrial natriuretic factor (ANF), growth
 hormone interactions and, 405
 in anxiety disorders, 404-405
 Attention, in geriatric population, 948
 Attention deficit disorder, cognitive
 executive circuitry in, 559
 Attention deficit hyperactivity disorder
 (ADHD), **761-774**
 characteristics of, 797
 comorbidity with, 767-768
 conduct disorder with, 768
 diagnosis of, Conners' Abbreviated Rat-
 ing Scale, for teachers, 765
 in adults, 764-767
 Parents' Rating Scale, 765
 Utah Criteria in, 764-767
 etiology of, 768-769
 dopaminergic hypothesis in, 768-69
 genetics in, 769
 inattentive subtype, missed diagnosis of,
 919-920
 natural history of, 768
 neuroimaging studies of, CT in, 741
 MR imaging in, 741-742
 SPECT in, 742
 obsessive compulsive illness and, 793,
 797-798
 prevalence of, 767-768
 psychotic symptoms in, 897
 symptoms of, in bipolar children and ad-
 olescents, 921-922
 treatment of, education in, 771
 pharmacologic, 770-771
 underdiagnosis of, **761-774**
 case presentations, adult, 761-762
 childhood of case subjects, 762-763
 differences in with diagnostic simi-
 larity, 764-767
 treatment of subjects, 763-764
 Atypical psychosis, **895-904**
 causes of, 896-902
 axis I disorders, 897-898
 axis II disorder, 898-899
 axis III disorders, 899-902
 cultural considerations and, 902-903
 definitions of, 895-896
 schizophrenia and, as typical psychosis,
 896
 unusual presentations of, 902
 typical versus, 896
 Audiogenic stress, in activation of brain
 structures, 267-268
 Auditory hallucinations, in dissociative
 identity disorder, 641
 violence and, 567
 Autism, childhood misdiagnosis of, as
 attention deficit hyperactivity
 disorder, 929-30
 as thought disorder or schizophrenia,
 930-931
 definition of, 928
 in adults, 928-929
 in children, prevalence of, 928
 prevalence of, 928
 Autointoxication, 662
 Autonomic system, regulatory role of, in
 drinking, 525
 in reproductive behavior, 526
 Avoidant personality disorder, descriptions
 of, 776, 782
 exclusionary conditions for, 785
 necessary conditions for, 783
 Awareness deficits, in schizophrenia, 35-39
 association with neuro-cognitive and
 affective deficits, 38-39
 measurement of, 36-37
 validity of, criterion, 38
 descriptive, 37-38
 Baclofen, as probe of growth hormone
 activity, 415
 Basal ganglia, in motor circuitry, 532-534
 re-entrant loops in, 535
 granular, 535
 structure of, intrinsic connections in,
 533-534
 striatum in, 532-533
 subthalamic nucleus in, 533
 Beers, Clifford, and mental hygiene
 movement, 236
 Behavior, in geriatric population, 948-949
 in seizure disorders, 629
 Behavioral disorders, typology with
 neuropathic association of, typology,
 630-631
 Behavioral strategies, for factitious
 disorder, 881
 Benzamide antipsychotics, 155-156
 Benzodiazepines, for delirium, in older
 patient, 959-960
 Bereavement, hallucinations in,
 misdiagnosis of, 921
 major depressive disorder in, 964
 Bipolar disorder, depression in, subclinical,
 282
 hyperthyroidism with, 908
 hypothyroidism in, 280-281
 in adolescence, missed diagnosis of,
 922-923

- in hyperthyroidism, 279
- MR imaging in, 743-744
- neuroimaging in, 743-745
- premenstrual effect on, 583
- risk factors for, childhood-onset depression, 934
- schizophrenia versus, in adolescents, 45
- thyroxine supplementation in, 284
- Bleuler, E., basic and accessory symptoms of, 29-30
- basic and accessory symptoms of, 29-30
- group of schizophrenias and, 27
- schizophrenia and, 27
- Borderline personality disorder,
 - descriptions of, 775, 781
 - exclusionary conditions for, 785
 - lying in, 873
 - necessary conditions for, 783
 - psychotic symptoms in, 898
 - violent behavior in, 568
- Brain, five-circuit model of, 519
 - brainstem: diurnal activity-rest, 519-522
 - psychiatric disorders and, 523-524
 - caudate nucleus: cognitive executive, 548-553
 - psychiatric disorders and, 554-560
 - hypothalamus: basic need, 524-529
 - psychiatric disorders and, 529-530
 - putamen: motor, 530-539
 - psychiatric disorders and, 539-541
 - ventral striatum: emotional motivational, 541-544
 - psychiatric disorders and, 544-548
- functional aspects of, 265-270
 - under acute restraint and swim stress, 266
 - under audiogenic stress, 267-268
 - under conditioned fear, 266-67
 - under defeat stress, 271
 - under peripheral interleukin stress, 265-266
- hippocampus, feedback inhibition of hypothalamic-pituitary-adrenal axis, 269-270
- in schizophrenia, 84-85
 - pathomorphology of, clinical correlates of, 85-86
 - etiopathologic significance of, 86-88
 - infections of, violence and, 570-571
 - tumors of, violence and, 569-570
- Brain circuits, in regulation of hypothalamic-pituitary-adrenal axis, 263-265
 - brainstem and medullary afferents, 263-264
 - circumventricular afferents, 264-265
 - mesopontine afferents, 264
- Brain functions and psychiatric disorders, 517-566. *See also Brain; Brainstem.*
- Brain imaging, in schizophrenia, chemical and physiologic, 93-122
 - structural, 77-92
- Brain injury. *See Minor head trauma.*
- traumatic, 735, 737
- SPECT in, 737
- Brain tumor, schizophrenia versus, 709-710
- Brainstem, diurnal activity-rest circuitry of, 519-522
 - ascending reticular activating system in, 519
 - brain injury effect on, 523
 - cholinergic reticular system in, 519-521
 - dopamine pathways in, 520-521
 - forebrain cholinergic system and, 521
 - norepinephrine pathways in, 520
 - REM sleep and, 522
 - serotonin pathways in, 520
 - sleep disorders and, 523-524
 - slow wave sleep and, 522
 - trimonamine modulating system in, 519-521
 - wakefulness and, 522
 - neuroanatomy of, functional, 519
 - psychiatric disorders in
 - criteria for, 523
 - delirium, 523
 - metabolic disturbances and, 523
- Bretazenil, as antipsychotic drug, 169
- Bromocriptine, as probe of growth hormone activity, 415
 - in hyperprolactinemia, 482-483
- Bulimia nervosa, clinical description of, 381-381
 - CNS neuropeptide function in, 383-384
 - leptin in, plasma and cerebrospinal fluid concentrations of, 386
 - neuroendocrine findings in, 382
 - neuroendocrine studies in, 382-383
 - neuropeptides in, 384-385
 - normal weight, vasopressin levels in, 388-389
 - oxytocin in, cerebrospinal levels of, 389
 - psychoneuroendocrinology of, CNS role in, 381-396
 - starvation in, 383
 - ventricular enlargement and relationship to HPA axis in, 469-470
- Bupropion, for attention deficit hyperactivity disorder, 770-771
- Carbamates, violent behavior and, 574
- Carbon dioxide inhalation, cortisol levels in, in panic disorder, 402
- Case Western Reserve University (CWRU), brain imaging studies of schizophrenia, in adolescents, 47-49

- Cataplexy, in narcolepsy, 597
- Catecholamine system, in trauma exposure, 368
- Catecholamines, levels of, comparison in major depression and posttraumatic stress disorder, 369-370
- metabolism of, in posttraumatic stress disorder, 370-371
- Caudate nucleus, cognitive executive circuitry in, 548-553
- association-1 loops in, 549
- association-2 loops in, 550
- hippocampal loops in, memory and, 550-553
- psychiatric disorders associated with, amnestic, 559
- criteria for, 554
- dementias, 558-559
- obsessive-compulsive disorder, 554-555
- schizophrenia and psychoses, 555-558
- Central sleep apnea, definition of, 595
- diagnosis of, 603
- pharmacotherapy for, 603
- treatment of, 596
- CFS. See *Chronic fatigue syndrome (CFS)*.
- Childhood schizophrenia, versus adult, 902
- Children, developmental and psychiatric disorders in, evolution into adulthood, 927
- missed diagnoses in, 927-940
- anxiety disorders, 936-937
- Asperger's syndrome, 928
- autism, 928-931
- developmental speech and language disorders, 931-932
- dyslexia, 932-933
- mood disorders, 933-934
- tic disorders, 936
- psychoneuroendocrinology in, 435-441
- Children and adolescents, schizophrenia in, 43-56
- CT studies of, 47
- epidemiology and diagnosis of, 44-46
- epidemiology of, 44-45, 45-46
- family issues in, 51-52
- first-break studies of, 44
- follow-up studies of, 44-45
- MR imaging and, 47-48
- neurodevelopmental versus neurodegenerative theories of, 47
- neuropsychiatric research in, 46-49
- neuropsychologic findings in, 48-49
- outcome studies of, 46
- pharmacotherapy of, 49-52
- clozapine in, 50-52
- comparison of thiothixene and thioridazine in, 49
- olanzapine in, 51
- risperidone in, 49-51
- ventricular brain ration in, 47-49
- Chlorpromazine, and early antipsychotic drugs, 153-154
- neuroleptic syndrome with, 151
- Cholecystikinin, in anxiety and panic disorders, 404
- Chronic fatigue syndrome (CFS), 671-692.
- See also *Fibromyalgia*.
- case definitions, Centers for Disease Control and Prevention, 674
- International Consensus Definition of CFS, 675
- clinical evaluation in, 675
- clinical management of, framework for, 684
- initial planning in, 684-685
- nonpharmacologic, 684-686
- nontraditional, complementary approaches, 687
- outcome assessment in, 684
- pharmacologic, 686-687
- physical activity in, 685-686
- psychotherapy, 686
- sleep renormalization in, 685
- co-occurrence of psychiatric illness in, 679-680
- diagnoses in, exclusionary, 675-677
- dilemmas in diagnosis and clinical management, 671-692
- formulation of illness and, 672
- historical perspective, 673
- neuroendocrine abnormalities in, comparison with fibromyalgia, 681-682
- overlap with fibromyalgia, 674, 677-678, 685
- overlap with psychiatric illness, 674
- pathogenesis of, neuroendocrine function studies for, 678-682
- pathogenetic theories of, chronic immune activation, 678-679
- corticotropin-releasing hormone with glucocorticoid excess, 680
- glucocorticoid deficiency, 681
- hypothalamic-pituitary-adrenal axis function, 680
- Circadian rhythm disorders, delayed sleep phase syndrome, 592-593
- insomnia and, 602-603
- Clomipramine (CMI) challenge, prolactin response to, 350-351
- Clonazepam, for rapid eye movement disorder, 595
- Clonidine, as probe, of growth hormone activity, 416
- of prolactin secretion, 417
- Clonidine challenge, growth hormone response to, 438-439

- of growth hormone, in panic disorder, 398-399
- Clozapine, cost-effectiveness of, 192-193
 - versus haloperidol, 193
- in schizophrenia, 170
 - for negative symptoms in, 159-160
 - in children and adolescents, 50-51
 - in treatment-resistant patients, 157-158
 - pharmacology of, 155
 - receptors of, 156-157
 - reduction in extrapyramidal side effects with, 156
 - treatment-resistant, 182
 - versus classic antipsychotic drugs, 159-160
- monitoring of, cost-effectiveness of, 193-194
- pharmacoeconomics of, 187-189, 192-194
 - clinical studies and, 188-189
 - conclusions of studies, 187, 192
 - tardive dyskinesia and, 156
 - versus traditional antipsychotics, cost of, 182
- Cocaine, abuse of, manifestations of, 813-815
 - putamen motor circuitry and, 540
 - stimulation of limbic system rewards, 547-548
- Cognitive functions, in geriatric population, 948-949
- Cognitive impairment, in hypothyroidism, 907
 - in schizophrenia, atypical antipsychotic drugs for, 161
 - ineffectiveness of classic antipsychotic drugs for, 160-161
 - prevalence of, 160
 - in seizure disorders, 629
 - in sleep apnea, 595
- Community service(s), for schizophrenia
 - treatment, assertive community treatment and case management, 224
 - efficacy of, 222-224
 - family, 223
 - psychologic, 222
 - public policy and, 228-229
 - vocational rehabilitation, 223
- Compensation neurosis, 884
- Complement proteins, in innate immunity, 444-445
- Complex partial seizures, behavioral
 - symptoms in, 627
 - differentiation from psychopathology, 632-633
- Compulsive disorders. *See also Obsessive-compulsive disorder (OCD).*
 - lying in, 874
- Computed tomography (CT), 727-728
 - advantage over MR imaging, 727-728
 - description of, 727
 - disadvantage of, 728
 - in attention deficit-hyperactivity disorder, 741
 - in mood disorders, 743
 - in schizophrenia, child and adolescent, 47
 - findings in, 77-78
 - structural brain imaging, 77-79
 - ventricular enlargement and, 78-79
- Concussion. *See also Postconcussion syndrome.*
 - grades of, 611
- Conditioning, pre-multiple chemical
 - sensitivity, 664
- Conduct disorder, cortisol levels in, in preadolescent boys, 436
- Consultation liaison psychiatry, importance of electrocardiography in, 711-712, 713
 - missed diagnoses in, 705-714
 - brain tumor versus schizophrenia, 709-710
 - hyperthyroidism versus major depression, 705-707
 - neurosyphilis versus manic episode, presenile dementia, 707-709
 - nonmotor status epilepticus versus psychotic depression, 710-712
 - psychotic depression in sepsis, 712-713
- Conversion disorder, characteristics of, 651
 - deception in, 874-875
- Cortex, in motor circuitry,
 - cytoarchitectonic organization of, 531-532
 - macroscopic organization of, 530-531
- Corticotropin-releasing factors (CRFs), and depression, 297-299
 - anxiogenic effects of, 298-299
 - function of, 294
 - immunosuppressive effects of, 453-455
 - in adrenocorticotropin hormone secretion, 262
 - neurons and receptors systems of, 298
 - stimulation of cytokine production, 453
- Corticotropin-releasing hormone binding protein (CRH-BP), 262
- Corticotropin-releasing hormone (CRH),
 - effect on GnRH secretion, 311-312
 - growth hormone release and, 332
 - in adrenocorticotropin hormone secretion, 262
 - in anorexia nervosa, 387
 - regulatory role of, in eating, 526
- Corticotropin-releasing hormone (CRH)
 - stimulation test, for Cushing's syndrome, 910

- Cortisol, circadian release of, 365
hypersecretion of, depression in children and, 436-437
hyposecretion of, association with externalizing disorders, 436-437
in aggression and antisocial behavior, in adults and children, 436
in schizophrenic patients, basal levels of, 418-419
stress effect on, 419
levels of, in combat veterans, 364-365
in posttraumatic stress disorder, 363-365
in sexually abused women, 364-365
in sodium lactate studies of panic disorder, 402-403
studies of, 364
response to dexamethasone, in posttraumatic stress disorder, 366-367
salivary levels of, in preadolescent boys with conduct disorder, 436
secretion of, in major depression, in adolescents, 437
Cortisol-releasing factors (CRFs) in anxiety states, 402-403
Cortisol-releasing hormone (CRH), cerebrospinal, effects of, 401
chronic stimulation of, pituitary hypertrophy with, 466
exhypothalamic, and hypothalamic-pituitary-adrenal axis, in anxiety disorders, 401-402
hypersecretion of, in posttraumatic stress disorder, 362-363
metyrapone stimulation test for, 363
Craniofacial dysmorphogenesis, in schizophrenia, 127-132
cellular and molecular biology of, 131-132
cerebrocraniofacial dysmorphogenesis, 129-131
timing of, 128
relationship of brain morphogenesis and craniofacial dysmorphogenesis, 128-129
topography of dysmorphology and, 127
CRFs. See *Corticotropin-releasing factors (CRFs)*.
CRH. See *Corticotropin-releasing hormone (CRH)*.
CT. See *Computed tomography (CT)*.
Culture, posttraumatic stress disorder and, diagnosis of, 843
psychotic behavior and, 902-903
Cushing's disease, psychiatric presentation of, 909
Cushing's syndrome, adrenocorticotropin hormone-dependent, 479
affective symptoms in, 479-480
clinical features of, 479
factitious, 910
mood disorders in, 296
psychiatric presentation of, 909-910
CWru (Case Western Reserve University), brain imaging studies, of schizophrenia in adolescents, 47-49
Cytokines, effect on hypothalamic-pituitary-adrenal axis, 456
proinflammatory, corticotropin-releasing hormone effect on, 453
in depression, 455-456
in stress, 449
DA. See *Dopamine (DA)*.
Daubert v Merrell Dow Pharmaceuticals, 851
Daytime sleepiness, in narcolepsy, 597
Cycloserine, in schizophrenia, 169
DDNOS (dissociative disorder not otherwise specified), 642-643
Deception, in abnormal illness behavior, 874-875
Defeat stress, in regulation of hypothalamic-pituitary-adrenal axis, 271
Deficit syndrome, in schizophrenia, 39
Dehydroepiandrosterone (DHEA), properties of, 497
Delayed sleep phase syndrome (DSPS), case study of, 592
diagnosis of, 593
phototherapy for, 593
Delirium, brainstem diurnal activity-rest circuitry in, 523
depression versus, 963
features of, 964
in geriatric population, 953-960
DSM-IV characteristics of, 954
evaluation of, electroencephalogram in, 958
neuroimaging in, 958-959
screening instruments in, 958
incidence and prognosis of, 953-954
neuropsychophysiology of, 955-956
nonpharmacologic, 959
outcome of, 954
postoperative, 957
risk factors for, 956-957
hospitalization, 956
neuroleptic malignant syndrome, 956
serotonergic syndrome, 956-957
treatment of, pharmacologic, 959-960
underlying mechanisms of, 955-956
in hypothyroidism, 907
in older adult, treatment of, implied consent in, 960

- withdrawal, benzodiazepines for, 960
- Delusional disorder, psychotic symptoms in, 897-898
- Delusions, paranoid, violence with, 567
- Dementia(s), Alzheimer's, 558-559
 - cognitive executive circuitry in, 558-559
 - depression-related, 951
 - features of, 964
 - frontal lobe, 559
 - in geriatric population, Alzheimer's, 949-953
 - cognitive functions in, 948-949
 - disorders producing, 950
 - recognition of, 946-947
 - reversible, 951
 - types and recognition of, 949-953
 - vascular, 951
 - in Parkinson's disease, 951
 - medication-related, 951
 - metabolic disorders and, 951
 - multi-infarct, 559
 - presenile, versus neurosyphilis, 707-709
- Dependent personality disorder,
 - descriptions of, 776, 782
 - exclusionary conditions for, 785
 - necessary conditions for, 783
 - response to clinical management in, 778
- Depersonalization disorder, causes of, 640
 - comorbid diagnoses in, 640
 - course of, 640-641
 - definition of, 640
- Depressed mood, in chronic fatigue syndrome, 679
- in fibromyalgia, 679
- Depression. See also *Major depressive disorder (MDD)*.
 - adrenal gland in, enlargement of, 466-467
 - as affective disorder versus insomnia-related, 601
 - childhood-onset, 934
 - correlation of hypercortisolemia and hippocampal atrophy, 468
 - corticotropin releasing factor and, 297-299
 - effect on diagnosis, of brain-injured patient, 617-618
 - features of, 964
 - following sleep disturbance, 601
 - from childhood abuse, 935
 - glucocorticoid receptors and, 297
 - glucocorticoids and, 295-296
 - gonadal-releasing hormone in, 314
 - growth hormone and, 325-339, 439
 - hippocampal changes in, 468-469
 - HPA axis dysfunction and ventricular brain enlargement in, 469
 - hypercortisolemia in, 312
 - hypothalamic-pituitary adrenal axis in, 293-307
 - hypothalamic-pituitary-adrenal axis in, 293-307, 496
 - preclinical studies of, 299-300
 - animal models, 299-300
 - epigenetic models in, 299
 - genetic models in, 299
 - hypothalamic-pituitary-gonadal axis in, 309-323
 - hypothalamic-pituitary-thyroid axis in, 497-498
 - hypothyroidism in, 280
 - subclinical, 281-282
 - immune system response to, 454-455
 - in childhood, misdiagnosis of, 934
 - in children, growth hormone response to
 - growth hormone releasing hormone in, 439
 - in Cushing's syndrome, 479-480, 909
 - in diabetes mellitus, 481
 - in eating disorders, 794
 - in geriatric population, treatment of,
 - nonpharmacologic considerations in, 964-965
 - pharmacologic considerations in, 965
 - in growth hormone deficiency, 481-482
 - in hyperprolactinemia, 482-483
 - in hyperthyroidism, 279, 908
 - in hypothyroidism, 475, 907
 - in older adult, as heterogeneous group of disorders, 961
 - course and outcome of, 963
 - diagnosis of, medical illness association in, 961-962
 - medication and, 962
 - differential diagnosis of, 963-964
 - DSM-IV criteria for, 962
 - presentation of, 960-961
 - prevalence of, 960-961
 - suicide and, 962-963
 - in premenstrual syndrome, 581-582
 - in schizophrenia, treatment guidelines for, 211
 - in sleep apnea, 595-596
 - in subclinical hypothyroidism, 475
 - neuroendocrine and immune system interaction in, 443-463 See also *Immune system*
 - immune response overview and, 444-447
 - neuroimaging studies of, 744, 745
 - pathophysiology of, immune system in, 445-456
 - PMDD and PMS-associated, 582
 - postpartum, 310
 - poststroke, 328
 - prevalence of, sex differences in, 309-310
 - prolactin and, 341-358
 - psychoneuroendocrinology of, brain imaging in, 465-472

Depression (*Continued*)

- psychotic, nonmotor epilepticus versus, 710-712
- versus delirium of sepsis, 712-713
- risk factors for, childhood onset depression, 934
- family history, 934
- ventricular brain enlargement in, hypothalamic-pituitary-adrenal axis and, 469
- Desipramine, and growth hormone response to clonidine, 329
- in growth hormone release, 328
- Dexamethasone suppression test (DST), as hypothalamic-pituitary-adrenal axis challenge, 496-497
- as stressor, 436
- cortisol response to, in major depressive disorder, 366-367
- in posttraumatic stress disorder, 366-367
- hypercortisolemia and, 295-296
- low-dose, in major depressive disorder, 367-368
- in posttraumatic stress disorder, 367-368
- results in schizophrenia, 419-420
- D-fenfluramine, as probe in schizophrenia, of adrenocorticotrophic hormone and cortisol, 420
- DHEA. See *Dehydroepiandrosterone (DHEA)*.
- Diabetes insipidus, psychiatric presentation in, 913
- Diabetes mellitus, clinical presentation and classification of, 480
- psychiatric disorders in, 481
- psychiatric presentation of, 911-912
- DIDs. See *Dissociative identity disorder(s) (DIDs)*.
- Disability syndromes, 883-885
 - case example of, 884-885
 - deception and detection in, 883-885
 - deception in, antecedent factors in, 883-884
- Disease management, in schizophrenia, implementation of, 226-227
- long-range goal of, 227-228
- practice guidelines and treatment recommendations for, 227
- Disgust, in psychiatric disorders, 545
- Dissociative amnesia, 637-638
 - concurrent symptoms in, 638
 - definition of, 637-638
 - diagnosis of, 638
 - DSM-IV definition of, 849-850
 - epidemiology of, 638
 - underdiagnosis of, 638
- Dissociative disorder not otherwise specified (DDNOS), 642-643
- culture-bound syndromes, 643
- derealization without depersonalization, 643
- phenomena in, 643
- trance possession versus, 643
- Dissociative disorder(s), 637-648
 - depersonalization disorder, 640-641
 - diagnosis of, Dissociative Experiences Scale in, 643-644
 - hypnosis in, 645
 - Minnesota Multiphasic Personality Inventory in, 644-645
 - sodium amytal interview in, 645
 - structured clinical interview in, 644
 - dissociative amnesia, 637-638
 - dissociative fugue, 638-640
 - dissociative identity disorder, 641-642
 - factitious, 642
 - not otherwise specified, 642-643
- Dissociative episodes, recurrent, in pseudoseizures, 652
- Dissociative fugue, amnesia in, 639
 - causes of, 639
 - comorbid diagnosis in, 639-640
 - definition of, 638-639
 - stress and, 639
 - underdiagnosis of, 639
- Dissociative hallucinosis syndrome, 921-922
- Dissociative identity disorders (DIDs), auditory hallucinations in, misdiagnosis of, 921
- cognitive executive circuitry in, 560
- concurrent symptoms in, 641
- diagnosis of, 641-642
- disorders confused with, 6452
- epidemiology of, 642
- individual personality states in, 641
- missed diagnosis in, 641
- Dissociative states, seizures and, 632
- DLPFC. See *Dorsolateral prefrontal cortex (DLPFC)*.
- Dopamine, prefrontal cortex and, innervation of, 64-65
- Dopamine agonists, as probes of growth hormone activity, 414-415
- presynaptic and partial, in schizophrenia, 167-168
- Dopamine autoreceptor agonists, selective, in schizophrenia, 168
- Dopamine (DA), and growth hormone release, 329
 - growth hormone regulation by, 414-415
 - in prolactin regulation, 416
 - in depression, 353
 - in prolactin secretion inhibition, 342
- Dopamine hypothesis, for schizophrenia and psychotic disorders, 556
- Dopamine receptors, antipsychotic drugs and, 155

- type II, in schizophrenia, in striatum/nucleus accumbens, 58-59
- Dopaminergic hypothesis, for attention deficit hyperactivity disorder, 769
- Dopaminergic system, hypoactivity of, attention deficit disorder and, 524
- in major depression, 546
- in mania, 547
- Dorsolateral prefrontal cortex (DLPFC), in schizophrenia, afferent input to, 66-67
- neuropil reduction in, 66
- Doxapram, as panicogen, 403
- Drinking, regulation of, by hypothalamus, 525-526
- Droperidol, for delirium, in older patient, 959
- DST. See *Dexamethasone suppression test (DST)*.
- Dwarfism, psychologic, 259-260
- Dynorphin, cerebrospinal fluid concentrations of, in anorexia nervosa and bulimia nervosa, 387-388
- Dysmorphology, topography of, 127
- Eating, regulation of, by hypothalamus, 526
- Eating disorders. See also *Anorexia nervosa*; *Bulimia nervosa*.
- amenorrhea in, 383
- obsessive compulsive illness and, 793-794
- pituitary imaging in, 469
- premenstrual effect on, 584
- selective serotonin reuptake inhibitors for, 798
- Elderly, demographics of, 941
- hyperthyroidism in, 908
- medical problems of, psychiatric symptoms in, 942
- schizophrenia in, 902
- subdivisions of, 941
- substance abuse disorders in, atypical presentation of, 823
- Electrical allergy, 662
- Electroconvulsive therapy (ECT), 494
- Electroencephalogram, in delirium, 958
- in pseudoseizures, abnormalities in, 650
- diagnosis of, 650
- Encephalitis, limbic, violence and, 571
- Encephalopathy, Lyme, 696, 698-699
- Endocrine disease(s), in factitious disorder, 878
- psychiatric presentations in, 905-916
- adrenal disorders, 909-910
- endocrine pancreas and, 911-912
- parathyroid disorders, 911
- pituitary, anterior and posterior, 913
- reproductive disorders, 912-913
- thyroid disorders, 906-909
- psychiatric presentations of, 905-916
- Endocrine disorder(s). See also *named, e.g., Thyroid disorder(s); Psychoendocrinology; Psychoneuroendocrinology*.
- adrenal system, 478-480
- diabetes mellitus, 480-481
- growth hormone, 481-482
- parathyroid, 477-478
- psychiatric morbidity in, 473-489
- reproductive disturbances, 482-483
- thyroid, 473-477
- Endocrine markers, of epilepsy, limitations of, 653
- Endocrine system, regulatory role of, in drinking, 525
- in eating, 526
- in reproductive behavior, 526-527
- β -Endorphin, cerebrospinal fluid concentrations of, in anorexia and bulimia nervosa, 387-388
- Environmental illness. See *Multiple chemical sensitivity (MCS)*.
- Epilepsy, catamenial, symptom overlap with PMS, 585
- pseudoseizure imitation of, 650-651
- psychiatric disorders associated with, consultation liaison psychiatry and, 711-712
- Epileptic syndromes, classification of, 626-627
- International League Against Epilepsy Commission classification of, 626-627
- EPSEs. See *Extrapyramidal side effects (EPSEs)*.
- Estradiol, in dopamine regulation, 422
- in schizophrenia, protective effect of, 425
- Estrogen, in schizophrenia, antidopaminergic activity of, 421-422
- glutamatergic effects of, 422-423
- medication effect on, 424
- neurotrophic/neuroprotective effects of, 422-423
- postpartum levels of, 426-427
- neurotropic and neuroprotective effects of, 422-423
- Estrogen supplementation, in augmentation of antidepressant therapy, for major depressive disorder, 317-318
- in major depressive disorder, 317
- with neuroleptics, in schizophrenia, 425
- Executive/yoke training stress, 270-271
- in regulation of hypothalamic-pituitary-adrenal axis, 270-271

- Expert Consensus Guidelines, for schizophrenia treatment, 205-206
- Extrapyramidal side effects (EPSEs), atypical antipsychotic drugs and, 154
- characterization of, 152
- with antipsychotic drugs, 152
- Factitious disorder, bleeding in, 878
- case example of, 875
- confrontational versus behavioral approach to, 881
- definition of, 875
- dermatitis artefacta in, 877-878
- diagnosis of, 877
- endocrine disease in, 878
- fever in, 877
- intentionality in, 875-876
- Munchausen syndrome in, 879-881
- prevalence of, 876
- psychiatric disorders in, 878-879
- psychological determinants of, 875
- psychotic symptoms in, 898
- treatment of, 881-882
- Factitious dissociative identity disorder, 642
- False memory, definition of, 857-858
- nonacceptance of, 858
- syndromes and, criteria for, 858
- use of against therapists, 857
- False Memory Syndrome Foundation, opposition to repressed memory concept, 854-855
- retrieval techniques versus existence/accuracy of repressed memory and, 856
- Family, National Alliance for the Mentally Ill and, 228-229
- of schizophrenics, adolescent, 51-52
- interventions for, 223
- support systems for, 213-214
- Fear, conditioned, in activation of brain structures, 266-267
- Fenfluramine, prolactin response to, in depression, 349-350
- in schizophrenia, 417
- Fertility, leptin modulation of, 386
- Fibromyalgia. See also *Chronic fatigue syndrome (CFS)*.
- case definitions of, American College of Rheumatology criteria for, 676
- clinical management of, framework for, 684
- initial planning in, 684-685
- nonpharmacologic, 684-686
- nontraditional, complementary approaches, 687
- outcome assessment in, 684
- pharmacologic, 686-687
- physical activity in, 685-686
- psychotherapy, 686
- sleep renormalization in, 685
- co-occurrence of psychiatric illness in, 679-680
- definitions of, American College of Rheumatology, 676
- operational, 675-676
- diagnosis of, exclusionary, 675-677
- historical perspective, 673-674
- neuroendocrine abnormalities in, comparison with chronic fatigue syndrome, 681-682
- overlap with chronic fatigue syndrome, 674, 677-678, 685
- pain modulation in, 674
- pathogenesis of, neuroendocrine function studies for, 678-682
- pathogenetic theories of, corticotropin-releasing hormone with glucocorticoid excess, 680
- glucocorticoid deficiency, 681
- hypothalamic-pituitary-adrenal axis function, 680
- pain dysregulation, 679
- slow wave sleep disturbances, 679
- prevalence of, 677
- Fibrositis, 673. See also *Fibromyalgia*.
- fMRI. See *Functional MR imaging (fMRI)*.
- Frontal lobe, in schizophrenia, MR imaging findings and, 82
- Fry v United States*, 849
- Functional magnetic resonance imaging (fMRI). See also *Magnetic resonance imaging (MRI)*.
- description of, 112-113
- in schizophrenia, 750-751
- studies of, 112-113
- Gamma-aminobutyric acid (GABA), growth hormone release and, 330-331
- Gamma-aminobutyric acid (GABA) agonists, 169
- Gamma-aminobutyric acid (GABA) neurotransmission, in schizophrenia, 62-63
- Ganser syndrome, 643
- Gender, schizophrenia and, 44, 103-104
- and structural brain abnormalities, 85
- correlation with brain pathomorphology, 85
- Generalized anxiety disorder, obsessive compulsive illness and, 794-795
- premenstrual exacerbation of, 583
- Genetic factors, and schizotypal personality disorder, 5

- in depression, 310
- in schizophrenia, adoption studies of, 3
 - familial aggregation, 2
 - genetic models for, 6
 - interaction of environment with, 1-2
 - measurement of, continuum approach, 5-6
 - morphogenesis and dysmorphogenesis, 131-132
 - quantitative traits, 6
 - schizotypal personality disorder, 3-5
 - susceptibility genes studies and, 7-8
 - twin studies of, 3
- in substance abuse disorders, 805-806
- Genetic predisposition, in attention deficit hyperactivity disorder, 769
- Geriatric psychiatry, identification and treatment of medical problems in, history in, 943-944
 - laboratory examination for, 945-946
 - physical examination in, 944-945
 - medical conditions in, missed diagnosis of, 943-946
- missed diagnoses in, 941-971
 - delirium, 953-960
 - dementia, 946-953
 - depression in, 960-965
 - medical conditions, 943-946
- GH. See *Growth hormone (GH)*.
- GHRH. See *Growth hormone-releasing hormone (GHRH)*.
- Giantism, pituitary, psychologic complications of, 482
- Gilles de la Tourette syndrome, putamen motor circuitry and, 540
- Glutamate neurotransmission, in schizophrenia, 63-64
- Glucocorticoid receptors, and depression, 297
 - lymphocyte, in posttraumatic stress disorder, 365-366
- Glucocorticoids, affective symptoms with, 296
 - and depression, 295-296
 - as immunomodulators, 452
 - diurnal rhythm of, 263
 - feedback inhibition of, 262-263
 - function of, 294-295
 - stress effect on, 451-452
 - synthesis and secretion of, 260-263
- Glutamate pyramidal neurons, of prefrontal cortex, in schizophrenia, 63-64
- Glutamatergic agonists, in schizophrenia, 169
- Glutamatergic system, in mania, 547
- Glutamine hypothesis, for schizophrenia and psychotic disorders
- Glutaminergic system, dysfunction of, in schizophrenia, 422-423
- Glycine, in schizophrenia, 169
- Gonadal dysfunction, causes and results of, 483
- Gonadal hormones, in schizophrenia, 421-427
- Gonadotropin-releasing hormone (GnRH), response to, in depressed women, 314-315
 - secretion of, corticotropin releasing hormone effect on, 311-312
 - hypothalamic control of, 311-312
 - in anorexia nervosa and amenorrhea, 313
- Gonadotropins, effects of hypothalamic-pituitary-adrenal hormones on, peripheral, 312
 - hypothalamic control of, 311-312
 - ovarian function and, 310-311
- Growth hormone (GH), as psychotropic substance, 334
 - disorders of, physical stature in, 481-482
 - psychiatric disorders in, 481-482
 - in depression, 325-339
 - in schizophrenia, 414-416
 - interaction with atrial natriuretic factor, in anxiety disorders, 405
 - pyridostigmine effect on, 330
 - release of, acetylcholine and, 329-330
 - clonidine-mediated, 327-328
 - corticotropin-stimulated, 332
 - desipramine-induced, 328
 - diurnal fluctuations in, 333
 - dopamine and, 329
 - gamma-aminobutyric acid and, 330-331
 - growth hormone releasing hormone-stimulated, 332-333
 - galanin and, 333
 - hypoglycemia and, 331
 - hypothalamic-pituitary-adrenal axis and, 333
 - monoamines and, 327-328, 331
 - noradrenaline and, 327-328
 - peptide-stimulated, 331-333
 - regulation of, 326-327
 - serotonin and, 329
 - thyrotropin-releasing hormone effect on, 332
 - response of, in major depressive disorder, in children and adolescents, 438
 - to pharmacological challenge, 438-439
- Growth hormone-releasing factor (GHRF), as probe of growth hormone activity, 415
- Growth hormone-releasing hormone (GHRH), in growth hormone release, 326-327
- Guilt, in psychiatric disorders, 545

- Hallmann's syndrome, 483
- Hallucination(s), auditory, 641
- hypnagogic, in narcolepsy, 597
- in adolescents, misdiagnosis of, 920-922
- in dissociative identity disorder, 681
- violence and, 567
- Hallucinogen abuse, manifestations of, 813-815
- Haloperidol, clinical economics of, medical costs and effectiveness outcomes in, 198
- for delirium, in older patient, 959
- Halstead-Reitan Neuropsychological Battery, in minor head injury, 616
- Hashimoto's thyroiditis (chronic lymphocytic thyroiditis), 280
- Head trauma, minor, 609-624
- Herpes simplex encephalitis, rage attacks in, 570
- Hippocampus, and feedback inhibition, of hypothalamic-pituitary-adrenal activity, 269-270
- atrophy with hypercortisolemia in depression, 468
- Hippocampus and entorhinal cortex, in schizophrenia, neuroanatomy and neurochemistry of, 59-60
- Hispanics, substance use and abuse among, 810-812
- Histrionic personality disorder, descriptions of, 776, 781
- exclusionary conditions for, 784
- lying in, 873
- necessary conditions for, 783
- Hormones, as therapeutic agents, 494
- HPA. See *Hypothalamic-pituitary-adrenal (HPA) axis*.
- HPG. See *Hypothalamic-pituitary-gonadal (HPG) axis*.
- HPT. See *Hypothalamic-pituitary-thyroid (HPT) axis*.
- Huntington's disease, schizophrenic-like symptoms in, 899-900
- violence in, 571-572
- Hydroxytryptophan probe, prolactin response to, 349-350
- Hypercortisolemia, in amenorrhea and anorexia nervosa, 312
- in major depression, 295-296
- with hippocampal atrophy, 468-469
- Hypercortisolism, 479-480
- Hyperparathyroidism, hypercalcemia in, 477-478
- mood and psychotic symptoms in, 477-478
- psychiatric presentation of, 911
- violence in, 573
- Hyperprolactinemia, amenorrhea in, 482-483
- depression and anxiety in, 482-483
- Hyperthyroidism, anxiety disorders in, 476
- anxiety in, 278
- clinical manifestations of, 476
- depression in, 279, 476
- description of, 278
- in elderly patient, 908
- in psychiatric patients, screening for, 909
- major depression versus, 705-707
- mania in, 279
- mood in, 278
- psychiatric presentations in, 908-909
- treatment of, 477
- Hypnagogic hallucinations, in narcolepsy, 597
- Hypnosis, diagnostic, for dissociative disorders, 645
- in repressed memory, courtroom attack on, 849
- scientific versus forensic truth issue and, 848-849
- Hypochondriasis, deception in, 874-875
- Hypocortisolemia, 909
- Hypocortisolism (adrenal insufficiency), affective syndromes and psychoses in, 480
- psychiatric presentation in, 910
- Hypofrontality, in schizophrenia, positron emission tomography finding of, 107
- Hypoparathyroidism, hypocalcemia in, 478
- psychiatric presentation of, 911
- Hypothalamic-pituitary-adrenal (HPA) axis, activation by stress, effect on immune system, 451-452
- and growth hormone release, 333
- antidepressant effect on, 300-301
- basic constituents of, 260-263
- corticotropin-releasing factor mediation of, 435-436
- dysfunction of, ventricular brain enlargement in, 469
- environmental challenge of, 436
- in depression See under *depression*
- hyperactivity of, 465-466
- in children and adolescents, 436-437
- in descriptive psychoneuroendocrinology, 493
- in internalizing and externalizing disorders, of children, 435-437
- in posttraumatic stress disorder, 361-368
- interaction with noradrenergic system, in panic disorder, 400
- regulation of See also *Afferent(s)*
- brain circuits in, 263-265
- executive/yoke training stress in, 270-271
- psychologic variables in, 270-272
- stress effect on, 294, 300
- uncoupling from noradrenergic system, in panic disorder, 400-401

- Hypothalamic-pituitary-gonadal (HPG)
axis, disturbances in, mental changes with, 498
in depression, 308-323
in posttraumatic stress disorder, 371-372
therapeutic arm of, 498
- Hypothalamic-pituitary-thyroid (HPT)
axis, alterations in, in posttraumatic stress disorder, 371
in depression, 497-498
in mood disorders. See *Mood disorders*
observations in endocrinology, 497
overview of, 277-278
- Hypothalamus, basic need circuitry of, 524-529
feedback loops in, 528-529
in drinking, 525-526
in eating, 526
in reproductive behavior, 526-527
mediation of endogenous systems and, 525
need satisfaction objectives and, 527
periodicity of, 527
contribution of, to survival and reproduction, 528-529
contribution to survival and reproduction, 528-529
dysfunction of, 529-530
feedback loops of, amygdalo-hypothalamic, 528
hippocampal-mammillary-thalamo-cingulate, 528
hypothalamo-hypophyseal, 528
function of, 524-525
psychiatric disorders and, body image, 529-530
criteria for, 529
eating disorders, 529-530
self-induced water intoxication, 529
sexual, 530
- Hypothyroidism, bipolar disorder with, rapid cycling, 475
cause of, 279-280
cognitive and psychotic symptoms with, 474-475
depression in, 280, 475
in bipolar disorder, 280-281
medications and, 283
physical manifestations of, 474
psychiatric presentations in, 906-908
subclinical, 280-282, 475
bipolar disorder in, 282
depression in, 281-282
prevalence of, 280
symptoms of, 280
thyroid hormone replacement in, 475-476
violence in, 572-573
- Hysterical disorders, pre-multiple chemical sensitivity, 664
- Hysterical symptoms, absence in pseudoseizures, 651
- ICD. See *International Classification of Disease (ICD)*.
- ICI 204,636. See *Quetiapine (ICI 204,636)*.
- Immune system, acquired immunity and, 445-446
immunoregulation and, 446-447
innate immunity and, 444-445
stress and, 447-450 See also *Stress, immune system and*
- Immunity, acquired, 445-446
innate, 444-445
mediators of, 444-445
- Inattention, impulsivity, and hyperactivity, in adolescence, attention deficit hyperactivity disorder misdiagnosis in, 919-920
- Inhalant abuse, manifestations of, 813-815
- Insight, in schizophrenia, 35-36
- Insomnia. See also *Sleep apnea*.
categories of, 601
causes of, 601-602
central sleep apnea, 603-604
circadian rhythm disorders, 602-603
medical conditions, 602
medications, 602
periodic limb movements of sleep, 603
psychiatric disorders, 602
psychophysiological, 603-604
substance abuse, 603
presenting as psychiatric disorders, narcolepsy, 596-598
parasomnias, 598-601
rapid eye movement disorder, 593-595
sleep-disordered breathing, 595-596
psychophysiological, 603-604
- Insulin coma, therapeutic, 494
- Insulinoma, psychiatric presentation of, 913
- Interleukin, administration of peripheral, in activation of brain structures, 265-266
- International Classification of Diseases (ICDs)*, schizophrenia in, criteria for, 31-32
- International Classification of Diseases (ICDs)*, edition 10, neurasthenia in, 673
- Irregular schedule disorder (hypernycthemeral syndrome), 602
- Judgment, in geriatric population, 948-949
- Klinefelter's syndrome, 483

- Kraepelin, E., adolescent onset psychosis and, 43
 dementia praecox and, lack of insight in, 35
 schizophrenia and, 27, 29
- Late luteal phase dysphoria (LLPD), panic in, 404
- Laterality, in schizophrenia, positron emission tomography finding of, 107
- Law in psychology and psychiatry, patient rights and, 848
 standard of care and, 847
- Learning problems, parental, occurrence in offspring, 933
- Leptin, effect on neuropeptide Y, 386
 plasma and cerebrospinal fluid concentrations of, in anorexia nervosa and bulimia nervosa, 385-386
- Lies and deception, clinical spectrum of, 873-882
 detection of deception and, 885-890
 communication clues in, 886-887
 detection interview in, 887-890
 case example, 888-889
 Cross Examination Clinical Interview for, 887-888
 incentive and, 889-890
 polygraph, 889
 psychological testing in, 889
 videotaped documentation, 889
 guidelines for, 885-886
 in abnormal illness behavior, 874-875
 in disability syndromes, 883-885
 in factitious disorder, 875-882
 in malingering, 882-883
 in personality and compulsive disorders, 873-874
 nature of, 870-873
- Lithium, and antithyroid antibodies, 282-283
 hypothyroidism from, 282-283
 with thyroxine, adjunctive, 497
- LLPD. See *Late luteal phase dysphoria (LLPD)*.
- Low self-esteem, from abuse in childhood, 935
- Lying, biology of, 870
 deception guilt in, 872
 detection apprehension in, 872
 functions of, psychological, 870-871
 separation and individuation, 871
 motivations for, 872
 neurobiology of, 871-872
 self-deception and, 871
 types of, 872
- Lyme disease. See also *Neuropsychiatric Lyme disease*.
 chronic fatigue syndrome/fibromyalgia overlap in, 694
 description of, 693
 diagnosis of, brain imaging studies in, 698
 cerebrospinal fluid studies in, 697-698
 ELISA in, 697
 Western Blot in, 697
 misdiagnosis of, 694-695
 neuropsychiatric, underdiagnosis of, 693-703
 overdiagnosis of, 694
- Lyme encephalitis, characterization of, 696
- Lyme encephalopathy, characterization of, 696
- Magnetic resonance imaging (MRI), 728-731. See also *Functional magnetic resonance imaging (fMRI)*; *Quantitative magnetic resonance imaging (QMRI)*.
 advances in, bounding box approach, 83-84
 cortical surface patterns in schizophrenia, 84-85
 morphometrics, 84
 capability of, 725-726
 comparison with CT, 728
 comparison with SPECT, 737
 description of, 729
 functional. See *Functional Magnetic resonance imaging (fMRI)*
- in attention deficit hyperactivity disorder, 741
- in mood disorders, 743-744
- in schizophrenia, 748-749
 abnormalities on, frontal lobe, 82
 subcortical and other, 80, 82-83
 temporal lobe, 79-81
 total cerebral volume studies, 84
 advantages of versus CT, 77-79
 child and adolescent, 47-48
 hippocampus/entorhinal cortex and, 60
 lateral ventricular enlargement in, 79
 research and, 83-84
 structural brain imaging studies, 79-83
 temporal lobe abnormalities in, 79-81
 volumetric studies of thalamus and, 749-750
 new developments in, 729
- Magnetic resonance spectroscopy (MRS), 729
 in schizophrenia, 751-752
in vivo in schizophrenia, description of, 94-95
 information from, molecular composition of phosphorus phenomena and phospholipid resonances, 96

- physiologic significance of mobile phosphorus phenomena and phospholipid resonances, 96
- information from ^{31}P phosphorus MRS, 95-97
 - high-energy metabolites, 95
 - information from ^1H proton MRS, 97
 - ^{31}P phosphorus, 94
 - in vivo* ^{31}P phosphorus MRS, 97-100
 - in vivo* ^1H proton MRS, 100-101
- Magnetoencephalography, 732-723
- Maintenance pharmacotherapy, in schizophrenia, dose adjustment in, 210
 - duration of treatment in, 210
 - guidelines for, 209-210
- Major depression, in children and adolescents, serotonergic abnormalities in, 437-438
- limbic system dysfunction and, negative motivator disorders in, 545-547
 - positive motivator disorders in, 547-548
 - negative motivators in, 546
 - neurochemical systems in, 546-547
 - versus hyperthyroidism, 705-707
- Major depressive disorder, childhood-onset depression association with, 934
- DSM-IV criteria for, 962
- obsessive-compulsive disorder and, 795-796
- Major depressive disorder (MDD), catecholamine levels in, in comparison to posttraumatic stress disorder, 369-370
- cause of, 293-294
- hypothalamic-pituitary-adrenal axis in, 362
 - characteristics of, 295
 - in children and adolescents, 436-437
 - in children and adolescents, growth hormone response in, 438
 - ovarian steroids for, 317-318
 - stress-diathesis theory of, 293
 - versus posttraumatic stress disorder, endocrine alterations in, 360
- Malingering, antisocial personality traits and, 883
 - as dissociative identity disorder, 642
 - deception and detection in, 882-883
 - definition of, 882
 - evaluation of, forced-choice measures in, 619-620
 - Minnesota Multiphasic Personality Inventory in, 620-621
 - motivation for, 882
 - psychotic symptoms in, 898-899
 - versus conversion disorder, 882
 - versus factitious disorder, 882-883
- Malnutrition, feeding behavior and, effect on, 389, 391
- Manganese, violent behavior and, 575
- Mania, limbic system dysfunction and, positive motivator disorders in, 547-548
- violent behavior in, 568
- Manic episode, versus neurosyphilis, 707-709
- Marijuana abuse, manifestations of, 813-815
- MCS. See *Multiple chemical sensitivity (MCS)*.
- MDD. See *Major depressive disorder (MDD)*.
- MDL 100,907, in schizophrenia, 167
- Medial parvocellular (mpPVO) neurons, afferents to, 263-265
 - in corticotropin-releasing factor production, 262
- Medical illness, depression in, 961-962
 - in older adult, depression associated with, 961-962
 - in psychiatric patient, underdiagnosis of, 905-906
 - missed diagnosis of, in geriatric psychiatric patient, 943-946
- Medical problems, of elderly, impact on psychiatric disorders, 942-943
- unrecognized, in geriatric psychiatry, 943-946
- Medication, depression from, 962
- Medications, psychosis from, 901-902
- Memory. See also *Repressed memory*.
 - declarative, 550-551
 - fallibility of, 853-854
 - hippocampal loops in, 550-553
 - in geriatric population, 948
 - traumatic, 552-553
 - working, 551-552
- Memory impairment, in hypothyroidism, 907-908
- Mental hygiene movement, 224
- Metabolic abnormalities, psychosis with, 901
- Metabolic disturbances, brainstem diurnal activity-rest circuitry in, 523
- Methylphenidate, as probe of growth hormone activity, 415
 - for attention deficit hyperactivity disorder, 770
- Methylphenidate challenge, for vasopressin secretion, in schizophrenia, 421
- Metyrapone stimulation test, for cortisol-releasing hormone hypersecretion, 363
- Migraines, catamenial, symptom overlap with PMS, 585
- Mini mental status examination, of older adult, 944-945

- Minnesota Multiphasic Personality Inventory (MMPI), in diagnosis of dissociative disorders, 644-645
- Minor brain injury, diagnosis of, measures of attention and concentration in, 616
- Minor head trauma, 609-624. See also *Postconcussion syndrome*.
brain injury claimants and, 617-618
clinical diagnosis of, clinical history in, 614-615
comorbid conditions and, 614-617
family reports in, 614-615
neuropsychological testing in, 615-617
definitions in, concussion, grades of, 611
diagnostic, 610-614
postconcussion syndrome, 610-611
posttraumatic amnesia, 611-612
diagnosis of, noncognitive, psychosocial, motivational factors and, 617-621
effects of, residual, 611-614
incidence of, 610
misdiagnosis of, 609
nondiagnosis of, 609
risk factors for, 610
symptom constellations in, 621-622
- Minor head trauma patient, complaints of, neuropsychological, 618-619
malingering in, forced-choice measures of, 619-620
Minnesota Multiphasic Personality Inventory and, 620
symptoms of, assessment of validity of, 619-620
expectancy of, 619
somatoform defenses and, 617, 619
- Missed diagnoses, and misdiagnosis, 659-670
in adolescents, 917-926
in children, 927-940
in consultation, 705-714
in geriatric population, 941-971
- Monoamines, and growth hormone release, 327-328
- Mood, thyroid hormone effects on, theories of, 285-286
- Mood disorders, antithyroid antibodies and, 282
anxiety relationship with, 547
hypothalamic-pituitary-adrenal axis and, 277-291
in Cushing's syndrome, 296
neuroimaging studies of, 742-746
CT, 743
in bipolar disorder, 743-745
in major depression, 744-745
in unipolar disorder, 744
MR imaging, 743-744
SPECT, 745-746
thyroid hormones in, for augmentation of antidepressants, 284
for potentiation of antidepressants, 283-284
versus schizophrenia, brain imaging studies of, 87
- Mood disorder(s), obsessive compulsive illness and, 795-796
- mpPVO. See *Medial parvocellular (mpPVO) neurons*.
- MRS. See *Magnetic resonance spectroscopy (MRS)*.
- Multiple chemical sensitivity (MCS), case examples of, 666-667
cause of, 662
psychologic, 662
diagnosis of, acceptors and, 666
as conditioned arousal and generalization, 664
as hysterical or somatoform disorder, 664
as iatrogenic, 665
obvious versus obscure in, 664
rule-out criteria for, 663-665
secondary gain and, 666
historical perspective on, 661-662
lack of support for, 662-663
ligation for, 663
proponents of, 663
secondary gain in, 666
symptoms in, 661
treatment of, behavioral deconditioning, 668
physical, 667-668
- Munchausen syndrome, antisocial and personality disorder criteria and, 880
case example of, 879
description of, 879
motivation for, 880
- Munchausen syndrome by proxy, 880-881
- Myxedema madness, 474, 573, 906
- NA (noradrenaline), and growth hormone release, 327-329
- Naloxone, inhibition of feeding by, 388
- Naltrexone, inhibition of feeding by, 388
- Narcissistic personality disorder, anabolic-androgenic abuse and, 832
descriptions of, 776, 781
exclusionary conditions for, 784
necessary conditions for, 783
- Narcissitic personality disorder, lying in, 873-874
- Narcolepsy, as diurnal activity-rest disorder, 524
case study, 596-597
cause of, 598
characterization of, 524, 597
in schizophrenia, 598

- incidence of, 597
- narcoleptic tetrad in, 597
- National Alliance for the Mentally Ill (NAMI), 240-241
- objectives of, 241
- National Institute of Mental Health (NIMH) Intramural Program, brain imaging studies of schizophrenia, in childhood-onset patients, 47-48
- Native Americans, substance use and abuse among, 810-812
- Natural killer (NK) cells, activity of, 448
- in innate immunity, 444-445
- Negative symptoms, in schizophrenia,
 - atypical versus classic antipsychotics for, 159
 - clozapine for, 159-160
 - prevalence of, 158-159
 - response to neuroleptics, 35
- Neural networks, in schizophrenia,
 - developmental origin of, 124-127
 - frontotemporal, pathophysiological heterogeneity in, 103
 - pathophysiology of, on neuroimaging, 124-125
- Neuresthenia, 662
- Neuroanatomy and neurochemistry, in schizophrenia, etiology and, 67
- of GABA interneurons, 62-63
- of glutamate pyramidal neurons, 63-64
- of hippocampus and entorhinal cortex, 59-60
- of prefrontal cortex, 60-62
- dopamine innervation of, 64-65
- of striatum/nucleus accumbens, 58-59
- synaptic pathology and, 65-67
- Neuro-cognitive deficits, in schizophrenia, 38-39
- Neurodevelopment and neuroprogression, in schizophrenia, craniofacial dysmorphogenesis and, 127-132
- from developmental origin to onset of psychosis, 132-134
- from onset of psychosis, static encephalopathy or disease progression, 134-136
- from origin to onset, development of psychosis, 133-134
- infant neurointegrative and childhood psychosocial sequelae, 133-134
- nature of progression in, 136-141
- network pathophysiology and, 124-127
- neurobiology of cell death and, 140-141
- progression in, nature of, 136-141
- Neuroendocrine window concept, 492-493
- Neuroimaging, brain-imaging techniques, 727-735
- CT, 727-728
- image interpretation in, brain symmetry in, 733, 735
- case example, 733, 736-737
- normal neuroanatomy and, 734-735
- MR imaging, 728-730
- MRS, 729
- perfusion studies, 729-731
- positron emission tomography, 731-732
- SPECT, 729-731
- future direction of, 752-753
- in anxiety disorders, 737-741
- in attention deficit hyperactivity disorder, 741-742
- in delirium, 958-959
- in Lyme disease, 698
- in mood disorders, 742-746
- in schizophrenia, 746-752
- in traumatic brain injury, 735, 737
- new technologies in, 725-726, 732-733
- Neuroimaging in psychiatry, 725-759
- Neuroleptic malignant syndrome, definition of, 151-152
- delirium in, 956
- Neuroleptic treatment-resistant patients, 157-158
- Neuroleptics, in factitious disorder, 881-882
- response to, correlation with neuroimaging abnormalities, 86
- structural alterations from, 102
- Neurologic examination, of older adult, 944-945
- Neuronal networks, in schizophrenia, activation studies with positron emission tomography and, 107-109
- Neuropeptide Y, animal studies of, 384-385
- cerebrospinal fluid concentrations of, in anorexics, 384
- description of, 384
- leptin effect on, 386
- Neuropeptides, alterations in, starvation-induced, 391
- CNS, in anorexia and bulimia nervosa, 383-385
- Neuropil, definition of, 66
- in schizophrenia, in dorsolateral prefrontal cortex, 66
- volume reduction of, 102
- synaptic, reductions in, 102-103
- Neuropsychiatric Lyme disease, case studies, attention deficit disorder versus Lyme encephalopathy, 698-699, 701
- depression versus Lyme encephalopathy, 699, 701

- Neuropsychiatric Lyme disease (*Continued*)
 multiple sclerosis versus Lyme
 encephalomyelitis, 699-701
 clinical manifestations of, 695-696
 encephalopathy, 696
 in adults, 696
 in children and adolescents, 696
 neurologic, 695-696
 psychiatric, 696
 diagnosis of, brain imaging studies, 698
 cerebrospinal fluid studies, 697-698
 Lyme serology, 697
- Neuroreceptor imaging, in schizophrenia,
 with positron emission tomography,
 109-110
- Neurosyphilis, manic episode, presenile
 dementia versus, 707-709
- NIMH. See *National Institute for Mental
 Health (NIMH)*.
- Nitric oxide (NO), in immune response to
 stress, 454
- NK. See *Natural killer (NK) cells*.
- NO (nitric oxide), in immune response to
 stress, 454
- Noncompliance, in schizophrenia,
 treatment guidelines for, 211-212
- Noradrenaline (NA), and growth hormone
 release, 327-329
- Noradrenergic system, in anxiety
 disorders, 399
 interaction with hypothalamic-pituitary-
 adrenal axis, in panic disorder, 400
 uncoupling from hypothalamic-pitu-
 itary-adrenal axis, in panic disorder,
 400-401
- Obsessive-compulsive disorder (OCD),
 cortical cognitive executive circuitry
 in, 554-555
 serotonergic system and, 555
 descriptions of, 776, 782
 exclusionary conditions for, 785
 psychotic symptoms in, 897
 response to clinical management, 778-
 779
- Obsessive-compulsive illness. See also
Obsessive-compulsive disorder (OCD).
 intercurrent, symptom complexes in, 799
 selective serotonin reuptake inhibitors
 for, 798
- Obsessive-compulsive personality disorder,
 778-779
- Obsessive-compulsive spectrum disorder,
 anxiety in, 798
 characterization of, 791
 comorbidities with, 793
 alcohol abuse, 796-797
 attention deficit hyperactivity disorder,
 793, 797-798
 eating disorders, 793-794
 generalized anxiety disorder, 794-795
 mood disorder, 795-796
 treatment considerations in, 798
 concept of, 792
 features common to, 792-793
 obsessive-compulsive personality disorder,
 obsessive-compulsive disorder
 and, 791-792
- Obsessive-dependent personality disorder,
 necessary conditions for, 783
- Obstructive sleep apnea, comorbid effects
 of, 595-596
- Oculogyric crisis, putamen motor circuitry
 and, 540
- Oculogyric loop, psychiatric disorders
 associated with, Gilles de la
 Tourette syndrome, 540
 oculogyric crisis, 540
 Parkinson's disease, 539-540
 psychostimulant drug abuse, 540-541
- Oculomotor loop, in motor circuitry,
 538-539
 psychiatric disorders associated with,
 539-541
- Olanzapine, 182
 characterization of, 162
 clinical economics of, clinical studies
 and, 191
 comparison with haloperidol, 197
 medical costs and effectiveness out-
 comes in, 198
 study classification in, 197
 in schizophrenia, negative symptom im-
 provement with, 163
 versus haloperidol, 162-163
 versus traditional antipsychotics, cost of,
 182
- Opiates, manifestations of, 813-815
- Opioid peptides, in anorexia nervosa and
 bulimia nervosa, 387-388
- Opioid receptor antagonists, inhibition of
 feeding, 388
- Organic states, toxin-induced, violence in,
 574-575
- Organophosphates, violent behavior and,
 574-575
- Outcomes research, in pharmacoeconomics
 of antipsychotic drugs, 185
- Ovarian function, gonadotropin control of,
 310-311
- Ovarian hormones, premenstrual
 syndrome and, 315-316
- Oxytocin, in anorexia nervosa, 388-389
 cerebrospinal levels of, 389
 in schizophrenia, secretion of, 420-421

- PACT (Program of Assertive Community Treatment), 224
- Panic attack, in mitral valve prolapse, atrial natriuretic factor and, 405
- Panic disorder. *See also Anxiety disorders.*
atypical, mimic of pseudoseizure, 652-653
cholecystokinin in, 404
cognitive executive circuitry in, 560
functional-anatomic correlates of, 399-400
growth hormone in, clonidine challenge of, 398-399
noradrenergic system-hypothalamic-pituitary-adrenal axis interaction in, 400
uncoupling of, 400-401
pentagastrin in, 404
PMDD and, 583
seizures and, 632
sodium lactate studies of, cortisol levels in, 402-403
- Paranoid personality disorder, descriptions of, 775, 781
exclusionary conditions for, 784
necessary conditions for, 783
- Parasomnia disorder(s), aggression in, 600-601
case study, 598-599
confusional arousal, 599
diagnosis of, 599
differential diagnosis of, 599-600
in children, 599-600
risk factors for, 599
sleep terrors, 599
sleepwalking, 599
versus REM behavior disorder, 600
- Parathyroid disorder(s),
hyperparathyroidism, 477-478
hypoparathyroidism, 478, 911
psychiatric presentation of, 911
- Parkinson's disease, as prototypical brain disease, 57-58
dementia in, 951
neurochemical deficits in, 57-58
putamen motor circuitry and, 539-540
- Passive-aggressive personality, response to clinical management, 778
- Passive-aggressive personality disorder, descriptions of, 776, 782
exclusionary conditions for, 785
necessary conditions for, 783
- Pemoline, for attention deficit hyperactivity disorder, 770
- Pentagastrin, in panic disorder, 404
- Peptide YY, cerebrospinal fluid concentrations of, 385
description of, 384
- Perception, in seizure disorders, 629
- Perfusion studies. *See Single photon emission computed tomography (SPECT).*
- Periodic limb movements of sleep (PLMS), insomnia with, 603
- Personality, in geriatric population, 948-949
- Personality disorders, clinical management of, patient responses to, 778-779
clusters for, anxious/avoidant, 776-777, 782
dramatic/erratic, 775-776, 781
odd/eccentric, 775, 781
comorbidity in, 775-789
case history, 786-788
definition of, 777-778
diagnosis of, difficulties in, 779-780
exclusionary criteria in, 780, 784-785
interpersonal descriptions in, 781-782
necessary conditions for, 780, 783
necessary criteria in, 782
overlap problem in, 780
impact of, 777
lying in, 873-874
premenstrual syndrome effect on, 585
psychotic symptoms in, 898-899
recognition of comorbidity in, 775-789
violent behavior in, 568
- PET. *See Positron emission tomography (PET).*
- Pharmacoeconomics, of new antipsychotics, definition of, 181-182
evaluation of, 183-194
recommendations for, 198-199
for schizophrenia, 181-202
indirect cost-containment factors in, 186
of novel antipsychotic drugs, risperidone, 189-191, 194-196
- Phencyclidine delirium, violence and, 568-569
- Pheochromocytoma, psychiatric presentation in, 910
- Phobias, in diabetes mellitus, 481
- Phototherapy, for delayed sleep phase syndrome, 593
- Pituitary disorders, psychiatric presentation in, 913
- Pituitary gland, function of, 277
in depression, hypertrophy of, 466
MR imaging of, 466
in eating disorders, MR imaging study of, 469
- PLMS (periodic limb movements of sleep), insomnia with, 603
- PMDD. *See Premenstrual dysphoric disorder (PMDD).*
- PMS. *See Premenstrual syndrome (PMS).*
- Polypharmacy, missed diagnosis of, in geriatric psychiatry, 943

- PORT. See *Schizophrenia Patient Outcomes Research Team (PORT)*.
- Position emission tomography, in generalized anxiety disorder, 739
- Positron emission tomography (PET), and schizophrenia, 106-109
 activation studies to target neuronal networks, 107-109
 description of, 106-107
 hypofrontality of, 107
 laterality of, 107
 neuroreceptor imaging, 109-110
 in schizophrenia, volumetric studies of thalamus and, 749
 limitations of, 752-753
- Positron emission tomography (PET) studies, 731-733
- Postconcussion syndrome, 610. See also *Concussion*.
 DSM-IV criteria for, 611, 613
- Postpartum depression, 310
 estrogen treatment for, 316
- Postpartum period, thyroid function during, 285
- Posttraumatic stress disorder (PTSD). See also *Anxiety disorders*.
 biologic research in, 359-360
 catecholamine levels in, alterations in, 368-371
 comparison with major depressive disorder, 369-370
 in response to provocation, 370-371
 resting, 369
 childhood, adult depression and anxiety from, 935
 cognitive executive circuitry in, 560
 diagnosis of, 359, 835-836
 clinical intuition in, 840-841
 Cultural Context Interview for PTSD and, 843
 humans as diagnostic instrument in, 840-841
 minimization of error in, recommendations for, 842-843
 self-report in, 842-843
 structured interviews in, 842
 test selection in, 842
 etiology of, 360
 hypothalamic-pituitary-adrenal axis in, 361-368
 adrenocorticotropin hormone response to, 362-363
 cortisol levels in, 363-365
 cortisol response to dexamethasone and, 366-367
 cortisol-releasing hormone hypersecretion in, 362-363
 lymphocyte glucocorticoid receptors in, 365-366
 hypothalamic-pituitary-gonadal system in, 371-372
 hypothalamic-pituitary-thyroid alterations in, 371
 in children, 934-935
 neuroendocrine findings in, interrelationships in, 372
 neuroimaging in, 740-741
 prevalence of, 361-362
 psychological features of, 835
 psychoneuroendocrinology of, 359-379
 risk factors for, 361
 stress response in, 361
 subtle presentations of, 835-845
 cobbled memories in, 837-839
 definition of, 838
 in obvious presentations, 836-837
 obvious aspects of nonobvious presentations and, 837-839
 overdiagnosis and, 837-840
 signs and symptoms without report of event, 838
 underdiagnosis of, 839-841
 versus major depressive disorder, endocrine alterations in, 360
- Practice guideline(s), advantages to use of, 203-204
 assessment of treatment outcome, 217
 for schizophrenia, 204-205
 American Psychiatric Association Guidelines, 206
 dissemination and implementation of, 217
 Expert Consensus Guideline Series, 205-206
 for maintenance pharmacotherapy, 209-210
 in management of comorbid syndromes, 210-212
 in pharmacotherapy for acute psychosis, 207-209
 in specific situations, 207-215
 Schizophrenia Patient Outcomes Research Team treatment recommendations, 206-207
 use of family-institutional support systems, 213-214
 use of psychosocial rehabilitation programs and, 214-215
 uses of, 217-218
- Praxis, in geriatric population, 948
- Prefrontal cortex. See also *Dorsolateral prefrontal cortex (DLPFC)*.
 in schizophrenia, cellular and subcellular abnormalities in, 62
 dopamine innervation of, 64-65
 dorsolateral, 61-62
 glutamate neurotransmission and, 63-64

- neuroanatomy and neurochemistry of, 60-62
 - serotonin modulation of, 65
 - volume reduction of, 100, 102
 - subdivisions of and hypofrontality, in schizophrenia, 61-62
 - Prefrontal lobotomy, 225
 - Pregnancy, development disturbance
 - during, neural networks and, 125-126
 - psychiatric presentation of, 913
 - schizophrenic risk factor in, 11, 15-16
 - thyroid function during, 285
 - Pregnenolone, in schizophrenia,
 - glutamatergic activity and, 423
 - Premenstrual dysphoric disorder (PMDD),
 - diagnosis of, DSM-IV criteria for, 581
 - symptom charting in, 579-580
 - pathogenetic studies of, 580
 - research criteria for, 578-579
 - benefits of, 580
 - concerns about, 581
 - treatment options for, 580-581
 - Premenstrual syndrome (PMS), and
 - ovarian hormones, 315-316
 - comorbidity in, 581-582
 - definition of, 577
 - diagnosis of, symptom charting in, 579-580
 - diagnostic dilemmas in, 579-590
 - differential diagnosis of, 581-582
 - effect of RU486 on, 316
 - leuprolide for, 316
 - medical conditions and, symptom overlap with, 585
 - worsening of, 585-586
 - prevalence of, 577
 - symptoms of, 577-578
 - PRL. See *Prolactin (PRL)*.
 - Progesterone, in anxiety disorders, 403-404
 - in premenstrual syndrome, 316
 - in schizophrenia, dopaminergic activity and, 423-424
 - glutamatergic activity and, 423
 - Program of Assertive Community Treatment (PACT), for schizophrenia, 242
 - Prolactin (PRL), depression and, altered
 - regulation in, 352-353
 - challenge studies of, 347
 - clinical studies of, in adolescents, 347
 - in adults, 344-347
 - in children, 347
 - in depression, 341-358
 - altered regulation of, dopamine in, 353
 - 5-HT receptor subtypes in, 352-353
 - lactotroph dysfunction in, 352
 - basal concentrations of, 344-345
 - circadian rhythms of, 346
 - diurnal rhythms, 344
 - nocturnal levels of, 346-347
 - in schizophrenia, 416-418
 - response to neuroleptics and, 416-418
 - inhibition of, 342
 - levels of, in schizophrenic versus normal subjects, 416-417
 - stress and, 482
 - release of, factors in, 343
 - hypothalamic extracts in, 344
 - serotonin system in, 343-344
 - secretion in schizophrenic patients, pharmacologic probes of, 417
 - secretion of, chronobiology of, 342
 - regulation of, 341-343
 - Prolactin (PRL) secreting cells, 341-342
 - Prolactinoma, psychiatric presentation in, 913
 - Pseudodementia, definition of, 963
 - depression versus, 963
 - Pseudohypoparathyroidism, 478
 - Pseudoseizure patient, neuropathology in, 652
 - Pseudoseizures, 649-658
 - behaviors in, 649
 - definition of, 649
 - diagnosis of, 650
 - clinical confounders in, 650-653
 - absence of hysterical symptoms, 651
 - co-occurrence of epilepsy, 651
 - electroencephalogram abnormalities, 652
 - epilepsy symptoms, 651
 - psychiatric illnesses resembling seizures, 652-653
 - seizure course and treatment response, 651-652
 - induction of seizures in, 650
 - versus epilepsy, 650
 - incidence of, in seizure populations, 650
 - misdiagnosis of, 649-650
 - clinician-based factors, biases, 655
 - cognitive focus, narrow, 654
 - countertransference barriers, 655
 - discomfort with psychiatric diagnosis, 655
 - hubris, 655
 - ignorance, 654-655
 - shame, 656
 - patient, ambivalence, 654
 - denial, 653
 - patient denial and, 653
 - patient-based sources of, 653-654
 - technical factors in, 653
- Psychiatric diagnosis, deception and
 - detection in, 869-893 See also *Lies and deception*
 - for schizophrenia, criteria for, 29-31

- Psychiatric diagnosis (*Continued*)
 reliability in, 28-29, 31
 validity and, 28-32
- Psychiatric disorders, diagnostic model of, developmental phases in, 517-518
- Psychiatric illness, medical comorbidity and, 905-906
- Psychoendocrinology. See also *Endocrinology disorder(s)*.
 descriptive, 492
 hormone use in, for evocation of mental response, 493
 neuroendocrine window concept in, 492-493
 postpsychotropic drug observations in, brain-pituitary connections, 495-496
 discovery of thyroid-releasing hormone, 495-496
 general, 494-495
 nosology, new, 494-495
 of hypothalamic-pituitary-adrenal axis, 496-497
 of hypothalamic-pituitary-gonadal axis, 498
 of hypothalamic-pituitary-thyroid axis, 497-498
 of psychopharmacologic advances, 494
 peptidology, 495-496
 radioimmune assay and, 495
 prepsychotropic drug observations in, 493-494
 strategies in, 492
 structure in, 491
 therapeutic, 492, 494
- Psychoneuroendocrinology. See also *Endocrine disorder(s)*.
 commentary on, 491-505
 growth hormone response to pharmacological challenge, in adults, 438
 in children and adolescents, 438-439
 of anorexia and bulimia nervosa, CNS role in, 381-396
 of anxiety disorders, 397-412
 of children and adolescents, 435-441
 hypothalamic-pituitary-adrenal axis in, 435-437
 serotonin in, 437-438
 of depression, brain imaging in, 465-472
 growth hormone and, 325-339
 hypothalamic-pituitary-adrenal axis and, 293-307
 hypothalamic-pituitary-gonadal axis and, 309-323
 prolactin and, 341-358
 of mood disorders, hypothalamic-pituitary-adrenal axis and, 277-291
 of schizophrenia, 413-434
 posttraumatic stress disorder, 359-379
 principles of, 259-276
- Psychophysiological insomnia, description of, 603-604
 treatment of, 604
- Psychosis, acute, pharmacotherapy
 guidelines for, choice of drug, 207-208
 dosage range, 208-209
 duration of trial, 209
 side-effect management, 209-210
 during perimenstrual phase, 584
 metabolic causes of, 901
 neoplastic causes of, 900-901
 neurologic causes of, 899-900
 pharmacologic causes of, 901-902
 seizure disorders versus, 629-631
 nonschizophrenic symptoms, 630
 schizophrenia, 629-630
- Psychosocial rehabilitation programs, in schizophrenia, usage guidelines for, 214-215
- Psychostimulant abuse, putamen motor circuitry and, 540
- Psychotherapy, for personality disorders, 779
- Psychotic disorders, cortical cognitive executive circuitry in, 555-558
 cytologic changes and, 557-558
 drug action model of, 556
 neurochemical hypotheses for, 556
- PTSD. See *Posttraumatic stress disorder (PTSD)*.
- Public health policy, in schizophrenia, 228-230
- Public health policy, community services, and outcomes, for schizophrenia, 221-231
- Putamen, motor circuitry and, basal ganglia in, 532-533
 cortex in, 530-532
 oculomotor loop in, 538-539
 tetradic loop system in, 534-538
 psychiatric disorders implicating motor loops, cocaine and, 540-541
 Gilles de la Tourette syndrome, 540
 oculogyric crisis, 540
 Parkinson's disease, 539-540
 psychostimulant drugs of abuse and, 540-541
- Pyridostigmine, as probe of growth hormone activity, 416
 effect on growth hormone, 330
- Quantitative electroencephalography, 732-733
- Quantitative magnetic resonance imaging (QMRI), in obsessive-compulsive disorder, 738
 structure in, 735

- Quetiapine (ICI 204,636), characterization of, 164
in schizophrenia, 164-165
- Rapid eye movement disorder (RBD), case study, 593-594
characterization of, 594
chronic, 594
diagnosis of, criteria for, 594-595
stress and, 594
treatment of, 595
- Rapid-eye movement sleep behavior (RSB), 591
- Reliability, of diagnostic system, 28-29
- Repressed memory. *See also False memory.*
avoidance of lawsuits and, 847-867
false memory syndrome and, 854-855
lawsuits against therapist, 859
patient, 860
perpetrator, 859-860
legal actions and, 849
literature review of, 849-857
dissociative amnesia in, 849-850
for accuracy of, 853-856
for existence of, 849-853
opponents and, 850-853
recovered memory therapy in, 850-851
repressed versus recovered memory in, 856-857
scientific studies in, 851-852
traumatic amnesia in, 849
suggestive influence and, 847
versus unforgotten memories, 854
- Repressed memory syndrome, definition of, 856
politics and, 856-857
- Reproductive behavior, regulation of, by
hypothalamus, 526-529
endocrine system in, 526-527
hypothalamus in, 526-527
- Reproductive endocrine disorders,
anorexia nervosa in, 912-913
- Restless leg syndrome (RLS), insomnia with, 603
- Risperidone, 182
characterization of, 165
clinical economics of, clinical studies and, 188-189
comparison with clozapine, 196
comparison with standard treatment, 195
in chronic schizophrenia, manufacturer-financed, 195-196
industry-sponsored, double-blind comparison with haloperidol, 195
medical costs and effectiveness outcomes in, 198
study classification by completeness of clinical and economic outcomes, 194
study limitations in, 196
in adolescents, 49-50
in schizophrenia, comparison with classic antipsychotic drugs, 165-166
efficacy for negative symptoms, 165-166
side effects of, 50-51
versus olanzapine, toxic dose of, 51
versus traditional antipsychotics, cost of, 182
- RLA (restless leg syndrome), insomnia with, 603
- RSB. *See Rapid-eye movement sleep behavior (RSB).*
- Sadness, in psychiatric disorders, 545-546
- Schizoid personality disorder, descriptions of, 775, 781
exclusionary conditions for, 784
necessary conditions for, 783
- Schizophrenia, 555-558
adrenocorticotrophic activity in, 418-420
advocacy, recovery, consumerism challenges for, 233-249
child and adolescent, 43-56
classic subtypes of, 32-34
community services for *See Community service(s), for schizophrenia*
cortical cognitive executive circuitry in, 555-558
cortisol activity in, 418-420
cytologic changes and, 557-558
deficit syndrome in, 39
definitions of, 30
dexamethasone suppression test results in, 419-420
diagnostic criteria for, 31-32
modification of, 29-31
reliability and validity of, 28-29
disease management in, 226-228
drug action model of, 556
environmental risk factors for, 10-14
cannabis use, 12
cerebral ventricular enlargement, 13
developmental abnormalities, 13-14
fetal maldevelopment, 12
general population birth cohort studies of, 14
perinatal and early childhood brain damage, 11-12
place and time of birth, 12
pregnancy and birth complications, 11
epidemiologic trends in, explanations for, 18-19

Schizophrenia (*Continued*)

- geographic variation, 17
- immigrant studies, 17-18
- incidence data and, 17-18
- prevalence data and, 16
- time and, 17
- epidemiology of, new versus classic, 1-25
- gender effects in, 421
- gene-environment interaction in, 14-16
- genetic factors in, 2-10
- genetic mechanisms in, 8-9
- gonadal hormones in, 421-427
 - estradiol, 422, 425
 - estrogen, 421-427
 - progesterone, 423-424, 427
- growth hormone activity in, 414-416
 - clonidine probe in, 416
 - dopamine agonist probes of, 414-415
 - dopamine and, 414
 - growth hormone releasing factor probe in, 415
 - response to neurotransmitter systems, 415-416
 - secretion abnormalities of, 414
- heterogeneity in, metabolic, 103-104
 - neuroanatomic, 100, 102
 - pathophysiologic, 103
- historical concept and terminology for, 27, 29
- in women, neurobiology of, 421
- MR imaging in, functional, 750-751
 - quantitative, 748-749
- MR spectroscopy for, 94-106
- neuroanatomy and neurochemistry in, 57-76
- neurochemical hypotheses for, 556
- neurodevelopmental and neuroprogressive processes in, 123-149
- neurodevelopmental model of, 100, 102-105
- neuroimaging studies of, 746-752
 - CT, 746-748
 - in older patient, 751-752
 - MR imaging, 746-750
 - ventricular enlargement and, 746-748
- neuropathology of, intrauterine disturbance and, 125-127
 - studies in, 125-127
- outcomes management of, 225-226
- oxytocin secretion in, 420-421
- paranoid versus nonparanoid, 32-33
- positron emission tomography in, 106-110, 749
 - after neuroleptic treatment of, 420
- prefrontal glutamatergic pathways and, 105-106
- premenstrual exacerbation of, 584
- presentation of, in adult, 902
 - in childhood, 902
- process model for, 135-136
- progression in, neuronal levels, 138-139
 - psychologic and developmental aging in, 136-138
 - relationship of brain growth to intracranial cavity growth, 138-139
- prolactin activity in, 416-418
- psychoneuroendocrinology of, 413-434
 - historical perspective on, 413
- psychopathologic domains and insight in, 27-42
- public health policy, community services, and outcomes for, 221-231
- seizure disorder versus, 630
- single-photon emission-computed tomography in, 110-112
- SPECT in, 750-751
- standards of care and clinical algorithms for, 203-220 See also *Practice guideline(s)*
- structural brain imaging in, 77-92
- symptoms of, seizures and, 629-630
- synaptic pruning in, 67, 104-105, 140-141
- treatment needs in, 243
- vasopressin secretion in, 420-421
- versus brain tumor, 709-710
- violent behavior in, 568
- water intoxication in, effects of, 421
- Schizophrenia Patient Outcomes Research Team (PORT), treatment recommendations of, 206-207
- Schizotypal personality disorder (SPD), descriptions of, 775, 781
 - DSM-IV diagnostic criteria for, 4
 - exclusionary conditions for, 784
 - genetics and, 5
 - necessary conditions for, 783
- Schneider, K., first rank symptoms of schizophrenia, 30
- Secondary gain, in disability syndromes, 884
 - in factitious disorder, 876
- Secrecy, in obsessive-compulsive illness, 792-793
- Sedative/hypnotic abuse, manifestations of, 813-815
- Seizure disorders, 625-635
 - affective disorders and, 631
 - affective disorders versus, 631
 - anxiety disorders and, 631-632
 - anxiety disorders versus, 631-632
 - behavioral disorder relationship with, 625
 - complex partial seizures and differential diagnosis, 632-633
 - differentiation from psychopathology, 628-629, 632-633

- dissociative states and, 632
- overlap with anxiety and panic attacks
 - symptoms, 631-632
- psychopathology of, 628-629
- psychosis and, 629-630
 - evaluation of psychotic symptoms in, 630-631
- seizures in, classification of, 626-627
 - precipitation of, 628
- Seizure disorders presenting with
 - psychiatric symptomatology, 625-635
- Seizures, behavioral phenomena with, 625, 629
 - classification of, in 1981, 626
 - in 1985 inclusive of epileptic syndromes, 626-627
 - pre-1980, 626
 - complex partial, behavioral symptoms in, 627
 - precipitating factors in, 628
- Selective serotonin reuptake inhibitors (SSRIs), for depression and premenstrual syndrome, 582
 - for eating disorders, 798
 - for obsessive compulsive illness, 798
 - prolactin response to, 350
- Self-deception, 871
- Self-report, diagnostic, in posttraumatic stress disorder, 842-843
- Serotonergic syndrome, delirium in, 955, 956
- Serotonergic system, in major depression, 546-547
- Serotonin (5-HT), and growth hormone release, 329
 - dysfunction of, in PMDD, 582
 - dysregulation of, in child internalizing and externalizing disorders, 437-438
 - in children and adolescents, aggression and, 438
 - in neuromodulation of prefrontal cortex, in schizophrenia, 65
 - precursors of, 347-349
 - 5-hydroxytryptophan, 349-350
 - l-tryptophan, 347-348
- Serotonin (5-HT) agonists, 352
- Serotonin (5-HT) hypothesis, for schizophrenia and psychotic disorders
- Serotonin (5-HT) receptor antagonists, prolactin response to 5-HT challenge and, 350-351
- Serotonin (5-HT) receptor antagonist(s),
 - MDL 100, 907, 167
 - risperidone, 165-166
 - sertindole, 166-167
- Serotonin (5-HT) receptors, antipsychotic drugs and, 155
 - in prolactin release, 343-344
- Serotonin (5-HT) releasing agents, d, l-fenfluramine, prolactin response to, 349-350
- d-fenfluramine, prolactin response to, 350-351
- Serotonin (5-HT) system, in prolactin release, 343-344
- Sertindole, characterization of, 166
 - in schizophrenia, 166-167
- Setpoint satisfaction, 527
- SIADH (syndrome of inappropriate antidiuretic hormone), psychiatric presentation in, 913
- Single photon emission computed tomography (SPECT), 729-733
 - advantage of, 730-731
 - and schizophrenia, 110-112
 - studies in, 111
 - symptom domains and, 110, 112
 - variability of, 110
 - description of, 110, 729-730
 - function measurement in, 729-733
 - in attention deficit-hyperactivity disorder, 742
 - in mood disorders, 745-746
 - in panic disorder, 739
 - in schizophrenia, frontal metabolism and, 750-751
 - limitations of, 752-753
- Sleep apnea, central, 595
 - diagnosis of, 596
 - obstructive, 595-596
- Sleep deprivation, parasomnias following, 599-600
- Sleep disorders, 591-607
 - missed diagnosis of, in geriatric psychiatry, 942
 - presenting as psychiatric disorders, 591-607
 - delayed sleep phase syndrome, 592-593
 - violence in, 572
- Sleep electroencephalogram, in diagnosis of seizures versus psychopathology, 632-633
- Sleep paralysis, in narcolepsy, 597
- Sleep state misperception syndrome, 604
- Sleep terrors (nightmares), 599-600
- Sleep-related breathing disorder. *See Sleep apnea.*
 - case study of, 595
 - differential diagnosis in, 595
 - incidence of, 595
- Sleepwalking (somnambulism), 599-600
- Social communication, regulatory role of, in drinking, 525-526
- Sodium amytal interview, for dissociative disorders, 645
- Somatization disorder, deception in, 874-875
- Somatiform disorder, pre-multiple chemical sensitivity, 664

- Somatomotor system, regulatory role of, in drinking, 525
 in reproductive behavior, 525
- Somatotropin (growth hormone), 325-326.
 See also *Growth hormone (GH)*.
- Somnambulism (sleepwalking), 599-600
- SPD. See *Schizotypal personality disorder (SPD)*.
- SPECT. See *Single-photon emission-controlled tomography (SPECT)*.
- Starvation, adaptation to, leptin in, 386
 comorbidity and, 383
- Status epilepticus, nonmotor, psychotic depression versus, 710-712, 712-713
- Stigma, of mental illness, 235
- Stress, dissociative fugue and, 639
 immune response to, biochemical mechanisms in, 454
 corticotropin-releasing factor in, 453-454
 hypothalamic-pituitary-adrenal axis in, 451-452
 neuroendocrine mechanisms in, 451-454
 sympathetic nervous system in, 452-453
- immune system and, 447-450
 adrenocorticotrophic hormone release in, 449
 animal studies of, 447-449
 cortisol-releasing hormone activity in, 449
 human studies, 450
 life stressors and susceptibility to viral infection, 450
 natural killer cell activity in, 448
 proinflammatory cytokine increases with, 449
 T cell proliferation in, 447-448
 neuroendocrine and immune system interaction in, 443-463. See also *Immune system*
 immune response overview and, 444-447
- Stress(es), in functional activation of brain structures, 265-270
 audiogenic, 267-268
 fear, conditioned, 266-267
 peripheral interleukin, 265-266
 restraint, 635
 swim, 635
- Striatum. See *Ventral striatum*.
 structural changes in, secondary to anti-psychotic therapy, 102
- Striatum and nucleus accumbens, dopamine type II receptors in, 59
 in schizophrenia, neuroanatomy and neurochemistry of, 58-59
- Structured Clinical Interview for Dissociative Disorders (SCID-D), 644
- Structured interview instruments, for posttraumatic stress disorder, 842
- Subclinical hypothyroidism (SCHT). See under *Hypothyroidism*.
 depression in, 475
- Subcortical regions, in schizophrenia, pathomorphology of, progressive, 100, 102-103
- Substance abuse, definition of, 829
 in schizophrenia, treatment guidelines for, 212
 missed diagnosis of, in geriatric psychiatry, 942-943
 premenstrual, 584-585
 violence with, 568-569
- Substance use disorder(s)
 abuse, criteria for, 804
 definition of, 829
 addiction, biopsychosocial model of, 809
 barriers to detection of, 816-827
 age-related, 820-823
 gender-related, 819-820
 in disabled individuals, 824
 in gays and lesbians, 824
 patient-related, 817-818
 physician-related, 816-817
 social and cultural, 821, 824
 clinical setting and detection of, 824-827
 behavioral assessment approach and, 825
 brief screening instruments for, 825
 consultation-liaison context, 825
 inpatient or outpatient context, 826-827
 definition of, 804
 dependence, criteria for, 804-805
 diagnosis and class of substance in, 808
 difficulties in diagnoses, 803-828
 drug categories and manifestations of, 813-815
 in adolescence, concurrent DSM-IV disorders in, 923
 indicators of, 923-924
 problems in diagnosis of, 924
 in elderly, atypical presentation of, 823
 lying in, 874
 physiologic changes with, age-related, 822
 substance-related, 813-815
 risk factors for, 805-806
 environmental, 806
 genetic, 805-806
 psychiatric comorbidities, 806-808
 social and cultural, 807, 809-816
 substance use, historical perspective, 803
 reasons for, 803
- Substances of abuse, stimulation of limbic system rewards, 547-548
- Suicide, in older adult, clues to, 962-963

- risk of, in temporal lobe epilepsy, 631
- Swim stress, 635
- Sympathetic nervous system (SNS),
 - immune response to stress and, 452-453
 - in stress response, 368
- Synapses, in schizophrenia, pathologic, 65-67
- Synaptic pruning, in schizophrenia, 67
 - from childhood to adolescence, 140-141
 - molecular and neurobiologic model for, 104-105
- Syndrome of inappropriate antidiuretic hormone (SIADH), psychiatric presentation in, 913
- T helper cells, in acquired immunity, 445-446
 - subsets of, 446-447
- Tardive dyskinesia (TD), characterization of, 153
 - mechanisms for, 153
- Temperament, preschool, as predictive of adult disorders, 936-937
- Temporal lobe, in schizophrenia,
 - abnormalities of, 79-81
 - MR imaging findings and, 79-81
- Temporal lobe epilepsy, characterization of, 627-628
 - clinical characteristics of, 627
 - diagnosis of, 633
 - suicide risk in, 631
 - symptoms and phases in, 627-628
- Tender points, in chronic fatigue syndrome and fibromyalgia, 678
- Tetrad loop system, in motor circuitry, 534-548
 - loops in, direct modulating, 537-538
 - direct motor, 534-536
 - indirect modulating, 538
 - indirect motor, 536-537
 - neurochemical modulation of, 539-541
 - projection fibers in, 534
 - psychiatric disorders associated with,
 - Gilles de la Tourette syndrome, 540
 - oculogyric crisis, 540
 - Parkinson's disease, 539-540
 - psychostimulant drug abuse, 540-541
- Therapeutic efficiency, in pharmacoeconomics, 183
- Thioridazine, pharmacology of, 155
 - reduction in extrapyramidal side effects with, 155-156
- Thiothixene, comparison with thioridazine, in children and adolescents, 49
- Thyroid disorder(s), hyperthyroidism, 476-477
 - hypothyroidism, 474-476
 - psychiatric presentations in, 906-909
 - violence in, 572-573
- Thyroid function, during postpartum period, 285
 - during pregnancy, 285
 - gender and, 285
- Thyroid function tests, for hyperthyroidism, 909
- Thyroid hormones. *See also Hyperthyroidism; Hypothyroidism.*
 - adjunctive use of, 497
 - as drug potentiators, 497
 - for potentiation and augmentation of antidepressants, 283-284
 - in depression, excess synthesis of, 278-279
 - inadequate production of, 278-282
 - in mania, 497
- Thyroid-stimulating hormone (TSH),
 - function of, 277, 473-474
 - response to thyroid-releasing hormone, in posttraumatic stress disorder, 371
- Thyrotoxicosis, 909
 - violence in, 572
- Thyrotropin-releasing hormone (TRH),
 - discovery of, 495-496
 - function of, 277-278, 473
 - growth hormone release and, 332
- Thyroxine, adjunctive, in bipolar disorder, 284
 - with lithium, 497
 - elevated, in depression, 279
 - potentiation of imipramine by, 497
 - therapeutic, mania from, 281
- Tic disorders, in children, 936
- Tobacco abuse, manifestations of, 813-815
- Toxicant exposure, missed diagnoses and misdiagnosis in, 659-670
 - carbon monoxide and, 659-660
 - lead and, 660
 - mercury and, 662
 - multiple chemical sensitivity, 661-663
 - diagnosis of, 663-667
 - litigation in, 663
 - treatment of, 667-668
- Toxins, violent behavior from, 574-575
- Trauma spectrum disorders, hallucinations in, misdiagnosis of, 921
- Traumatic amnesia, 849
- Trimonamine modulating system,
 - regulatory role of, in eating, 526
- Tumor necrosis factor (TNF), in innate immunity, 444-445
- Turner's syndrome, 483
- Tyson v Tyson, 849
- Underdiagnosis of neuropsychiatric Lyme disease, 693-703

- Utah Criteria, for attention deficit hyperactivity disorder, in adults, 764-767
- Validity, of diagnostic system, criteria for, 28-29
 of psychopathologic domains, in schizophrenia, 34-35
 of schizophrenia diagnosis, 32, 34-35
- Vasopressin, in anorexia nervosa, 388-389
 secretion of, in schizophrenia, 410-421
- Ventral striatum, emotional motivational circuitry in, 541-544
 cortical evaluator pathways in, 541-542
 limbic basal ganglia input loops in, 541
 limbic motivators in, 543-544
 neurochemical modulation of, 544
 subcortical involuntary pathways in, 542-543
- limbic dysfunction, and associated psychiatric disorders, 544-548
 criteria for, 544
 negative motivators in, 545-47
 neurochemistry of, 547-548
 positive motivators in, 547-548
- limbic loop in, social motivators of, 543
- Ventricular brain ration (VBR), in schizophrenia, child and adolescent, 47-49
- Ventricular enlargement, in schizophrenia, child and adolescent, 46-47
 on CT, 78-79
 on MR imaging, 79
- Violent behavior, alcohol-induced, 568
 brain infection-related, 570-571
 brain tumor-related, 569-570
 during sleep, 598-599, 600-601
 from vitamin deficiencies, 573-574
 in Huntington's disease, 571-572
 in hyperparathyroidism, 573
 in limbic encephalitis, 571
 in manic state, 568
 in personality disorder, 568
 in schizophrenia, 567-568
 in sleep disorder, 572
 in thyroid disorders, 572-573
 in Wilson's disease, 571
 substance abuse-related, 568-569
 toxin-induced, 574-575
- Violent patients, unusual diagnoses among, 567-576
- Viral infections, aggression in, 570-571
- Vitamin deficiencies, violence and, 573-574
- Water intoxication, self-induced, hypothalamus and, 529
- Wechsler Intelligence Scale III, in minor head injury, 616
- Wechsler Memory Scale III, in minor head injury, 616
- Wilson's disease, violence in, 571
- Wisconsin Card Sorting Test, in minor head injury, 616
- Women, depression in, 309-310

